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On tärkeää tutkia yrityksiä, jotka etsivät ja luovat uusia markkinoita, erityisesti kun ne kokevat 
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Tutkimuksen kohdemarkkina (bioteknologia) on yksi korkeariskisimmistä ja kompleksisimmista, 
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myös tärkeää sopeuttaa yrityksen kumppanuusmallivalikoima kohdetoimialaan. Bioteknologiassa 
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1. INTRODUCTION 
Firms entering new markets had been studied for decades when by the 1990s, scholars noted 
a shift in the dynamics of many industries: the rise of importance of partnering. It refers to 
the increasing influence of partnership networks, and is part of a shifting balance from 
regional towards global, traditional manufacturing towards innovative business logics, from 
mature technologies and industries towards emerging ones, from ownership towards 
partnerships, from value chains towards value networks, from materials towards services and 
so forth.  
This study participates in the actively ongoing updates on market entry and partnering theory, 
from the point of view of a market entry taking place from a traditional industry to an alliance 
centred one. The study offers new knowledge and contribution by combining classic and 
recent theories of partnering and market entry in a theoretical framework designed to study 
partnering in de alio context (entering an unfamiliar industry), and applying it to analyse a 
challenging case. 
From the viewpoint of firms, nation states, societies, employees and citizens, finding and 
creating new markets and entering them successfully is very important; especially when the 
firms are experiencing pressure in their traditional, mature markets. When the overall market 
situation is hard, well informed strategic choices play an ever more important role in the 
success and survival of firms. Here, research can help to make even better informed choices 
in the future by analysing the deeper dynamics and making visible the invisible foundations 
of the options and choices. This adds further practical importance to the study as the case 
may offer insight for other companies planning to execute similar diversification endeavours 
as a part of their strategy. 
1.1 Partnering in de alio context  
The research context is that a multinational corporation (MNC), incumbent in a mature, 
material manufacturing industry, has identified an opportunity for expansion and renewal. It 
commercializes a new product into an emergent market in an unfamiliar industry, which is 
an extremely demanding and interesting strategy. The more common, familiar and less 
demanding commercialization within the home industry or a neighbouring industry had not 
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been chosen due to the lack of a suitable business model, and hence the company opted for 
the more demanding strategy. 
Furthermore, the case target market, the biotechnology industry, is ranked one of the most 
high-risk and complex, involving deep science, regulation, and learning race competition 
dynamics. Due to the risks, it has developed into a highly networked and symbiotic industry, 
where products and services may be produced by various entities interconnected in a network, 
instead of in-house.  
On top of this, the case company faces the extra challenges of de alio diversification, 
ambidexterity and the entry timing of an emergent market with accelerating competition. For 
example, a de alio newcomer tends not to have enough knowledge, networks or access in the 
target industry. All these factors contrast with the case company home industry which is 
more calculated and mature, and where the company enjoys the incumbent position. Even 
the competitive advantages the company has in the home industry are not guaranteed to apply 
in the target industry without adaptation.  
For all the above mentioned, a target industry partner is important and the partnering issues 
of de alio companies merit attention. Moreover, it is important to study the market entry and 
partnering strategy of de alio firms, since it is the foundation for the success of the market 
entry. Changing this strategy choice later on is not simple or easy and the costs of an 
erroneous choice can be substantial.  
Therefore, the focus of the research is, how can companies alleviate de alio market entry 
challenges by partnering. Furthermore, this study was executed in a research project between 
the case company and Aalto University School of Business, and this collaboration ensures 
the applicability of the research in a realistic environment.  
1.2 Research problem and gap 
The main research problem of the study focuses on how companies can manage the 
challenges of de alio market entry by forging partnerships. With whom, why and how to 
partner in the case context? 
In order to fulfil the academic objective of this study, I will combine, complement and extend 
existing partnering and market entry theories to the extent possible in a Master’s Thesis. The 
aim is to provide new insights into their applicability in analysing de alio market entries in 
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complex global industry contexts. Therefore, although prior research in the area of new 
market entry, partnering and choosing entry mode is considerable, the context and specific 
focus of my research renders it original. I comment especially on the topics where 
contribution is solicited in the academic community, such as the role of ecosystems and 
networks in entry processes, a processual view of partnering and market entry, entry learning, 
the connection of resources, abilities and timing of entry, and innovation-entry relations 
(Zachary et al., 2015, p. 1389, p. 1393; Journal of Management Studies 2016). 
Furthermore, the research is inspired by the observation that neither classic nor recent 
literature on market entry fully cover the entry of traditional manufacturing MNCs with a 
new innovative product into unfamiliar, emergent markets with completely different 
business logics. As Dunning argued in his update of the eclectic theory in 1995, globalization 
is changing the traditional manufacturing industries towards the rise of importance of 
partnering. The literature is keeping up with the change by covering the changing factors one 
by one. However, an overall picture has not formed yet (as a contrast to the classic, 
overarching paradigms), which is indicated by the need to combine various recent theories 
in order to research a case that contains various new factors. It is important to complement 
the literature to cover this phenomenon which forms an important part of the changing and 
complex reality of global industries.  
Ambidexterity models, for example, can be used as ingredients for complementing and 
extending theory. They usually concern new business development of one technological or 
product field inside one industry or two neighbouring industries, but even they do not fully 
cover the shift from mature into emergent when it takes place between industries and in more 
complex contexts.  
1.3 Research objectives and questions 
In this study, my aim is to contribute new perspectives in the academic field of market entry 
and partnering strategy. In the wider sense, the study sheds light on the execution and 
challenges of bold and exceptional renewal strategies of companies. Here, these refer to a 
combination of innovation and de alio diversification into another industry. In the process, 
my aim is also to distil practical new knowledge for the company. 
In the first place, the research process was started by reviewing literature based on the 
preliminary research problem statement. Furthermore, in the two preliminary focusing 
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interviews and group discussions with the company representatives, I could further specify 
the problem statement. In order to reach the aims, I investigate how different actors perceive 
the biotechnology industry segment, the drivers, the networks and the actors in them. I then 
analyse the motivations, advantages and disadvantages of the different strategy options, 
dynamics and conventions of the target market. The timing, competitive outlook and players’ 
positioning in the segment play an important role as well. Furthermore, it is necessary to 
understand the characteristics of the entering company, the product, the amount and nature 
of the resources available for the market entry. 
After reviewing the literature and conclusions from the preliminary focusing interviews, 
partnering was chosen as the focus. Firstly, partnering is a common tool when entering 
unfamiliar markets in general and biotechnology industry in specific, and secondly, the MNC 
also considers partnering a key focal point for the entry strategy. 
In order to investigate the kind of partner types, constellations and modes that would be 
possible for the MNC in the given context, it is important to know the reasons why the 
company considers a partner necessary instead of acting alone. This refers to the needs of 
the company or the type of advantages it seeks that the partner could contribute. Conversely, 
the company must be aware of what kinds of assets or advantages it is able or willing to offer 
so that a partner would be interested in partnering with a newcomer in the industry.  
Consequently, the main research problem and focus of this study is, how can companies 
manage the challenges of de alio market entry by partnering. The research questions used to 
investigate the research problem are: 
1. Who are the key partners/partner types in this context? 
2. Why de alio needs and wants to partner in this context?  
3. Which are the possible ways how to partner in the biotechnology industry and 
especially with Big Pharma?  
All in all, in order to address the described research problem, and complement the extant 
theories, the detailed objectives of the research are: 
1. Review existing literature related to companies commercializing new products in 
unfamiliar, emerging markets with a different business logic. 
2. Examine the needs, motivations and targets involved in market entry and partnering 
in de alio context. 
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3. Investigate the partnering network, dynamics, conventions and modes typical in the 
particular segment of the biotechnology industry. 
4. Assess the possible market entry modes that can be used to fulfil the market entry 
and partnering targets of de alio companies. 
5. Analyse challenges and possible solutions related to de alio market entry and 
partnering modes. 
1.4 Definitions of key concepts 
Ambidexterity: In organizations, it is understood as the ability to be successful at both 
exploiting the present and exploring the future (O´Reilly & Tushman, 2004, p. 2). In practical 
terms, an ambidextrous organization has differentiated the new venture from the core 
business in the organizational structure in order to allow for different types of business logics, 
yet maintaining coherence via close senior management cooperation. 
Biotechnology: According to (United Nations’ Convention on Biological Diversity 1993, 
Article 2), biotechnology means “any technological application that uses biological systems, 
living organisms, or derivatives thereof, to make or modify products or processes for specific 
use”. On the other hand, according to Pisano (2006, p.11, p.16), biotechnology includes 
technologies for drug R&D based on scientific advances in biology, molecular biology, cell 
biology, chemistry, biochemistry, genetics, genetics engineering, computer science, 
bioinformatics, mathematics, physics, engineering and medicine. 
Biotechnology industry: According to Burrill (2007), the biotechnology industry started to 
develop in the 1980s with close links to the pharmaceutical industry. A biotechnology firm 
is advancing, creating or commercializing new technologies for drug discovery in contrast 
to using traditional synthetic chemistry (Pisano, 2006). According to Stremersch and Van 
Dyck (2009), biotechnological medical devices are considered one of the core industries of 
the Life Science industry (along with pharmaceutical and therapeutic medical devices), while 
cosmeceuticals, medical devices and equipment, and nutraceuticals are considered boundary 
industries.  
De alio: The phenomenon is understood as diversification of a company into an unfamiliar 
market or industry. The term is often contrasted with de novo which means that the company 
was “born” in the industry in question (Agarwal & Moeen, 2015).  
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Market entry; entry mode strategy: The definition by Root (1983, 1994) is said to be the 
“bedrock” of market entry mode definitions. According to Root, market entry is the entry of 
a firm’s products, technology, human skills, management or other resources into a foreign 
country (Sharma & Erramilli 2004, p. 2). Recent theories take into account the effect of 
globalization: the entry not primarily to a geographical location but a global market segment. 
Consequently, entry mode is an institutional arrangement that makes the market entry 
possible. Entry modes in practice include a spectre of arrangements, for example, export 
(direct, indirect, own channels or intermediaries), wholly owned subsidiaries (greenfield or 
acquisition), joint ventures (majority, minority or equal ownership) and contractual modes 
(licensing, franchising or management contracts). 
Partnering: The concept of partnering has experienced shift of meaning as described for 
example by Dunning (1995). In the classic theories, organizational arrangements were 
categorized in full ownership, partial ownership and market transaction type contractual 
agreements. Of these, full ownership and contractual agreements were not considered 
partnering. Hence, the classic concept of partnering revolved around shared ownership. At 
the same time, this category of organizational arrangements was considered exceptional and 
non-preferred. The rise of importance of partnering described by Dunning includes the 
expansion of collaborative atmosphere to contractual agreements (Dunning, 1995; Powell, 
1998). Furthermore, partnering is no longer restricted or based on shared ownership only. 
The key focus now is in building trust, common goals, synergies and long-term relationships 
(Chesbrough & Schwartz, 2007). 
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2. LITERATURE REVIEW 
In this literature review chapter, existing relevant theories and concepts on partnering will 
be presented, and extended as necessary. I will form the basis for the review of the market 
entry literature in applicable parts and complement it with new business development theory, 
market entry timing theory and partnering theory. 
Longitudinal review of partnering related theories is important because it reflects both the 
development and changes in the business dynamics caused by globalization and the 
respective response in the literature development. In the case context, the classic theories 
correspond to the case company home market dynamics of traditional manufacturing and the 
more recent theory updates correspond to the target market dynamics of partnering and 
innovation centeredness. Complementary theories correspond to those somewhat extreme 
context aspects, which are not fully covered by the partnering related theories or which 
require combining separate theories. I will combine these in the theoretical framework 
presented at the end of the chapter.  
2.1 Partnering transition from one world to another 
Sharma and Erramilli (2004) place the starting-point of market entry mode research in the 
year 1976. Since then, the field has seen three paradigms and at least six major theories in as 
little as four decades of research (Sharma & Erramilli, 2004).  
The entry mode theories have looked at the strategy of entry mode focusing in different areas 
of it: the market, the firm, the nature of the product, the resources. The different entry modes 
and the theories thereof have also been classified in different ways, for example, according 
to equity/non-equity, inside-out/outside-in, location of production and marketing, the level 
of: risk, control/ownership, required commitment of resources, expected return-on-
investment and other desired outcomes.  
One of the most esteemed theories is the classic eclectic theory of Dunning (1980). In this 
study, it is especially useful, as Dunning has updated the theory in 1995 to respond to the 
changes in dynamics described by him as “the Rise of Alliance Capitalism” brought on by 
the globalization. This updated version of the theory will be referred to as updated eclectic 
theory in the rest of the study. Furthermore, Dunning’s two versions of the theory reflect the 
key aspects of the classic theories and the recent theories (and their development). 
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In both versions, Dunning approaches market entry strategy through three aspects, the 
interpretation of which changes to correspond the changes in business reality. These aspects 
are ownership related advantages (O), location advantages (L) and internalization 
advantages (I). In the following these aspects are used to highlight the key factors of the 
classic theories that correspond to the traditions of the case company home industry and the 
more recent theories that correspond to the dynamics of the partnering and innovation 
centred target industry. Furthermore, two case context key factors not fully covered by these 
theories will be approached through complementary theories on de alio, industry lifecycle, 
and ambidexterity. 
2.1.1 Partnering and market entry in the home industry tradition 
Reflecting the key factors of the case context, the focal points of the classic market entry 
theories can be summarized in five aspects. 
First, in the classic theories, internalization (I), control and full ownership are in a key role 
when obtaining and using resources. The main motivation for partnering in classic theories 
is mitigating risks when full ownership is considered too risky in a foreign country. Also in 
the traditional view, according to Dunning (1995, p. 462), “most contractual arrangements 
were considered as market transactions - even in situations in which there was some element 
of a continuing and information sharing relationship” between the participants. The 
motivations are further discussed in section 2.2 and the mode preferences in section 2.3. 
Secondly, the bedrock of entry mode theories is the assumption that the primary motive for 
market entry is to exploit a firm’s sustainable and transferable, ownership-specific (O), 
monopolistic/competitive advantage (such as a differentiated product or a proprietary 
technology) to obtain above normal returns and the activity is seen as production and 
marketing of the product. Hence, according to Sharma and Erramilli, the theories assume 
that the lack of such advantages probably minimizes the firm’s operations in the target 
market, as it is more typical to rely on a company’s existing resources to compete than 
develop new ones (Sharma & Erramilli 2004, pp. 3-9).  
Thirdly, the entry mode theories tend to concentrate on countries and locations (L), entering 
the target market in a geographical sense, which is often signalled by the use of terms such 
as “foreign country”, “home country” and “host country” in the definitions and theories of 
entry modes (see for example Sharma and Erramilli 2004, p. 11; Peng, 2001). This is one 
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possible point-of-view in the multi-layered reality of global business, and these obviously 
are unavoidable and important factors in our physical world, yet these are no longer a main 
focal point in all cases due to globalization. 
Fourthly, the entry mode theories tend to assume that the firm enters the target market in the 
same industry as in the home market, or a neighbouring one. This is understandable as these 
are the most common alternatives but it is also important to account for diversification to an 
unfamiliar industry as in the case context. 
And finally, fifth, the existing entry mode theories tend to assume an existing, established 
market which the firm wishes to enter. However, in the case context the target market is in 
an emergent life cycle stage. 
2.1.2 Partnering and market entry in the target industry tradition 
Reflecting the key factors of the case context, the recent market entry theories re-interpret 
the five focal points. Indeed, the more recent literature on market entry recognizes the 
changes taking place in the global industries, for example, Dunning (1995, 1998) named the 
phenomenon the rise of alliance capitalism. 
Firstly, in his updated eclectic theory, Dunning (1995) argues that alliances can be utilized 
as quasi-internalization (I) by forming trust-laden long term partnerships and hence avoiding 
the disadvantages of full ownership. Powell (1998) agrees, contending that it is not necessary 
to have ownership in order to reap the benefits. 
On the other hand, the views on alliances have changed concerning the contractual 
arrangements as well, in the other end of the continuum of partnership modes. In the more 
recent view (Powell, 1998), contractual transactions also include a more collaborative 
atmosphere and may include aligning business models. Moreover, Pisano (2006, p. 162) 
emphasizes that “whether value will ultimately be created depends on the execution of the 
[partnering] project”. Thus, the focal point has shifted from the mode choice to quality and 
maintenance of relationships. This reflects a shift from the event point of view to the 
processual approach. 
Secondly, in the recent theories, the competitive advantage focus has shifted from exploiting 
existing advantages to also developing new competitive advantages. Sharma and Erramilli 
(2004, p. 6) recognize that not all resources are “ready to use” but may only become sources 
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of competitive advantage after finding synergy with target market resources or a partner’s 
resources. Dunning (1995) concludes: 
It also needs to be more explicitly acknowledged that firms may engage in FDI and 
in cross-border alliances in order to acquire or learn about foreign technology and 
markets, as well as to exploit their existing competitive advantages. (Dunning 1995, 
p. 481) 
Dunning hence updates the eclectic theory by arguing that technological accumulation and 
learning should be identified as ownership-related (O) advantages of firms. 
Peng (2001, p. 812) summarizes the view that capability to learn from partners is key. 
Especially so for MNCs entering unfamiliar markets, where obtaining target market 
knowledge is crucial: 
capabilities to learn from partners may be a tacit resource underlying a firm’s 
competitive advantage [...]. For example, learning from partners is found to 
represent a primary motivation for firms to enter alliances […]. For MNCs, the 
intensity and diversity of learning from local partners facilitate local knowledge 
acquisition and strengthen firm performance in host countries […]. For local firms, 
learning from MNC parents is likely to enhance survivability and performance. 
(Peng 2001, p. 812) 
Creating a win-win with partners is possible, as target market firms may consider partnering 
with a MNC as enhancing their performance - and survival chances. 
Thirdly, in the face of the changed interplay between global and local, some researchers are 
using more general terms “home market” and “host market” (Ito & Rose, 2002), instead of 
the traditional “country” (for example Peng, 2001). This may also reflect the profound shift 
that has taken place from a nation-state centred world view to a global one. In this study, I 
consider that interpreting terms such as “local” and “host countries” in terms such as “target 
market” is possible, with due adjustments. 
In the globalized world, the role of physical locations (L) in global industries is present 
mainly in two aspects. On one hand, it is in the practical marketing and distribution activities, 
in concrete physical locations. On the other hand, the market has not developed similarly in 
all regions or countries due to business environmental differences such as resources available, 
regulation and local subsidies (Maine et al, 2014), creating city or regional clusters or 
“hotspots”. New entrants in emerging industries tend to cluster in a few locations that have 
a strong and balanced ecology of research centres, talented human resources, excellent 
transportation, communication and other assets supporting innovation (Maine, 2014, p. 5).  
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Dunning (1995, pp. 479-480) also includes the dynamics of clusters in his update of the 
eclectic theory locational (L) factors. He argues that often several bilateral relationships are 
needed at the same time, hence the location of a constellation of partners is important when 
deciding the location of an operation. Furthermore, additional benefits may arise such as the 
static agglomerative economies, increased opportunities for networking, easier gathering and 
dissemination of information, cross-fertilization of ideas and learning experiences, and 
finally, possible government support measures to such clusters (Dunning 1995, pp. 479-480). 
Especially the networking, information and learning related benefits are relevant to the case 
at hand, as they support access and learning which are two key factors discussed later in the 
study. 
While taking into account the role played by the locational factor, this study prioritizes the 
global viewpoint, because the biotechnology industry is primarily global although it operates 
according to the local dynamics in each country. Various realities are present simultaneously. 
Fourthly, the recent theories keep assuming that market entries tend to take place in the 
same industry or the neighbouring one. Finally, fifth, the recent theories also keep 
assuming an established market into which the entry takes place. These two factors form 
part of the somewhat extreme nature of the case context and need to be covered by 
combining, complementing and extending the market entry theories with complementary 
theories on de alio, industry life cycle and ambidexterity. This aims to contribute to the 
existing theory literature field. 
All in all, it has been said that entry mode choice has received enormous attention from 
researchers in international business (Sharma & Erramilli, 2004). Indeed, the current 
understanding of the entry mode strategy field is such that the need for more entry mode 
studies has been sharply questioned in the academic community, suggesting that saturation 
point has been reached and latest studies have offered little new, rather more of the same old 
(Shaver, 2013). This argument, however, has sparked a strong response. The argument in 
favour of continuing the study of entry modes and ideas for some future avenues of research 
are presented by for example Hennart and Slangen (2014), Zachary et al (2015) and the call 
for papers of the Journal of Management Studies (2016).  
As a researcher, I, too, believe that new points-of-view will always be presented, even though 
a brief stagnation might take place in the process. The object of research, that is, business 
and its environment will not freeze but keep changing, and hence, research must keep up and 
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keep interpreting it with new theories as old ones no longer seem valid. For example, the 
“end of history” was thought to be at hand when the Soviet Union collapsed (Fukuyama 
1992) but obviously this was not the case. Paradigms and theories have changed various 
times in the history of entry mode research as well, why would it stop here? 
2.1.3 Comparing the two partnering traditions 
The research at hand will take into account the debated “saturation” of the above reviewed 
literature, yet the case and the context investigated requires that the market entry and 
partnering strategy be approached from yet another different point of view or combination 
of them. The revised views of Sharma and Erramilli, Dunning and Peng describe the case 
context better than the traditional interpretations, yet they call for extension or combining 
with other theories in order to fully apply to the case at hand. In the following, I will review 
the five key factors (internalization, ownership-specific assets, role of locations, de alio 
diversification, emerging target market) highlighting where the case context is aligned with 
the theories and where its extreme features require complementary literature. The summary 
of the differences and comparisons can be seen in Figure 2.1.  
 
Figure 2.1. Comparison of classic theory, recent theory and case context factors 
Firstly, as in the recent theories, the target industry, that is, biotechnology industry, is highly 
partnering centred. However, the classic perspective is also present in the case context in the 
form of the home industry traditions on full ownership versus partnering. Indeed, one of the 
aims of this study is to investigate these ambidextrous dynamics.   
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Secondly, as in the recent theories, in the case context, the de alio parent company is not 
primarily exploiting existing competitive advantages but aiming to create new ones. The 
parent is not the entity possessing the relational assets (that is networks), intellectual assets 
(that is knowledge about market conditions, stakeholders, etc.) or other classic superior 
resources mentioned by Sharma and Erramilli, and the venture or the target market partners 
are not the entities absorbing them. Therefore, it is critical for the market entry that the de 
alio case company obtain resources (especially knowledge, networks, access) from its target 
market partners and is capable of absorbing them. It can also be argued that on the contrary 
of possessing specific knowledge that can be converted into products and competitive 
advantage as the theories assume, the company started the venture with little target market 
specific knowledge, and instead possesses a product that it wishes to use in order to produce 
knowledge. The entry and partnering strategy are motivated by the venture and the partners 
acting as learning tools to produce new assets (especially knowledge) for the parent, and 
funnelling information flows to the parent instead of only transferring knowledge and 
resources from the parent to the venture and partners. However, both the new venture and 
target market partners may indeed benefit from learning from the MNC its general strengths 
and business knowledge. 
Thirdly, as in some of the recent theories, in this case, the market is not primarily a 
geographical one but a global segment and industry. The markets of a global industry are 
multi-layered and have global, regional and national, even sub-national levels. Furthermore, 
classic market entry theories and some of the recent ones as well tend to pair the market 
entry with internationalization. However, the shift to a global business reality has required 
that this point-of-view become multi-layered as well. In this case, the de alio entrant 
company is a MNC and the target market segment is also global. This starting-point creates 
a very different context compared to a firm which is internationalizing for the first time or 
has little international activities, and also very different compared with the context of a small 
born-global (Oviatt 1995, 2005; Gabrielsson et al. 2004, 2008; Laanti et al. 2006).  
Nevertheless, in the globalized world the role of physical locations (L) in global industries 
is present mainly in three aspects. This means, a) the strong regulation of the biotechnology 
which may vary depending on the region for example between the EU, non-EU European 
countries and the US. Then, b) the very geographical, physical market entry will obviously 
need to take place especially in the form of distribution strategy, but this too is viewed as 
entering various regions/countries at once. The strategy needs to tackle the practical 
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distribution challenges and the strategic question of whether to market, sell and distribute 
the product directly from the headquarters, via subsidiaries and/or via distributors. The 
geographical context of the commercialization here is broadly Europe- and US-based, yet as 
the other actors in the target industry and market are international/multinational players, the 
focal point of the research is multinational (Maine, 2014). Moreover, c) it means the role 
played by the biotechnology hotspots or clusters of organizations, agglomerated in one small 
geographical area.  
Fourthly, although the recent theories are relatively better equipped for the case context than 
the classic ones, the case context is somewhat extreme for both classic and recent theories. 
This is because the multinational corporation, an incumbent in its industry and the home 
market, is adopting an ambidextrous renewal strategy of entering a new market segment with 
a new product in an industry where it has practically no previous position anywhere in the 
world. It enters “de alio”. It has manufacturing (home) industry advantages and capabilities 
of an incumbent, but these are not directly transferable to the very different dynamics of the 
target market, and need to be coupled with a considerable amount of learning and adaptation, 
more and different from entering the usually assumed same or neighbouring industry. The 
product in itself is not yet clearly differentiated and although the proprietary technology and 
its property rights are a key asset, similar technologies and products are available. In order 
to fully cover these contextual key factors, in the following sections I will apply the 
complementary theories concerning de alio diversification and ambidexterity. 
Fifth, the classic nor recent theories account for entering a new, emerging, non-mature 
market. They do not fully cover the de alio ambidextrous diversification either. However, in 
the case context, the target market is in a state of change which is reminiscent of an emerging 
market stage. In order to cover these key factors of the case context, in the following section, 
I will present the industry lifecycle theory. Finally, in the following section I will combine 
the de alio diversification, industry lifecycle and ambidexterity theories into one novel 
interpretation in order to extend and contribute to the theory field.  
As a summary, it can be said that the classic theories and the more recent theories are 
differently equipped to analyse the case at hand. Neither of them covers it fully, the case 
context being somewhat extreme. In the ambidextrous duality of the case context, classic 
theories correspond to the traditions of the case company home industry and the more recent 
theories correspond to the dynamics of the partnering and innovation centred target industry. 
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In order to cover fully an ambidextrous case with home industry and target industry, the 
study also needs to use both sets of theories to analyse the transition from one to the other.  
2.1.4 Between two worlds: de alio, ambidexterity and window of opportunity 
As it was noted in the previous section that the extant market entry theories did not fully 
cover all of the case key aspects, in this section I will review complementary theories related 
to the case context in order to extend the market entry theories. The aim is to account for the 
case context specifically on the two aspects calling for extension: the entry to an unfamiliar, 
non-neighbouring market (de alio) and the time dimension, that is, the emergent life cycle 
stage of the target market. 
2.1.4.1 Role of the de alio factor in the market entry 
To examine the de alio entry to an unfamiliar industry, the classic Ansoff Matrix (Ansoff, 
1957) serves as a starting point. It offers four strategies according to whether the product to 
be marketed and the market that is targeted are new/unfamiliar to the company. Two of the 
four strategies can be considered de alio: expanding the market of the existing company 
products to a new market or industry, or creating new products for a new market or industry. 
The interpretation of the matrix suggests that the newer aspects are involved in the process, 
and the further it reached from the familiar old business realm, the more demanding is the 
strategy. An adaptation of the matrix in Figure 2.2 shows the analysis of the aspects in the 
case situation: the knowledge and competences to be utilized in the commercialization of the 
new innovation are new, and so is the business. The situation corresponds to the 
diversification strategy of the Ansoff matrix, generally considered the most demanding of 
the four growth strategies. 
 
Figure 2.2. Adaptation of the Ansoff matrix depicting the situation of the de alio company 
The need to learn and develop new competences and assets is a central factor in the target 
industry dynamics and in the recent partnering centred market entry theories. The fact that 
the case context includes de alio diversification practically means that it further intensifies 
the learning need of the entrant.  
 16 
2.1.4.2 Role of the window of opportunity in the market entry 
Apart from the point of view of the company, considering the newness of the product and 
business, competencies and the unfamiliarity of the target market, the Industry Life Cycle 
Theory offers a view into the general development stage of a given market. The industry life 
cycle development curve is presented in Figure 2.3. Depending on the focal point of each 
author (Gustafsson at al. 2015; Peltoniemi 2011, 2014; Agarwal & Bayus 2004; Bayus & 
Agarwal, 2007; Suarez et al., 2015), the early phases of the life cycle consist of two or three 
phases: an emergence and growth phase or alternatively, an emergence, co-evolutionary/co-
development and growth phase. In the theories of the first kind, this case context takes place 
in the emergence phase, while in the theories of the second kind, the case takes place in the 
co-evolutionary/co-development phase. However, the key aspect to note that the phase in 
question is the one before growth phase: when the segment is no longer brand new but a 
dominant design has not yet emerged either. 
 
Figure 2.3. Representation of the industry life cycle including the co-development phase 
In the case of a de alio entry, industry life cycle stages of two markets will need to be 
considered: the home market of the company and the target market of the commercialization.  
Figure 2.4 shows an adaptation of the Life Cycle theory with the case company markets 
indicated in red. The multinational parent company operates in a mature material industry 
where it is an incumbent. With its new venture it is reaching into a market that is in a co-
evolutionary/co-development or emerging phase. According to Peltoniemi (2011, pp. 350-
354), the emergence phase is characterized by technological innovation, entry of a large 
number of firms and population level learning and building of legitimacy. The mature phase 
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on the other hand is characterized by process R&D (instead of product R&D), a dominant 
design, shakeout and consolidation in number of firms 
The industry life cycle stage also defines the market entry environment characteristics further, 
and offers an idea of the time dimension for the commercialization. The rise of a dominant 
design marks the end of co-evolution/co-development or emergence and signals the 
beginning of the rapid growth phase where dynamics change from R&D and numerous 
entries towards consolidation/shakeout and economies of scale. The time frame available for 
commercialization and successful market entry therefore means the time left for preparing 
for the shakeout, as the case company has decided to enter before it. In the literature, there 
is debate (Lieberman, 1988; Peltoniemi, 2014) on the pros and cons of entering early (before 
the appearance of a dominant design) and late (after appearance of a dominant design). 
According to Peltoniemi (2014) large de alio companies mostly enter late in order to exploit 
their competitive advantages in economics of scale. This underlines the special natures of 
the case context, as the MNC has decides to enter early.  
 
Figure 2.4. Adaptation of the Life Cycle theory with the case company markets indicated 
in red 
2.1.4.3 Role of ambidexterity in the de alio diversification strategy 
As the two markets and industries where the company is to operate simultaneously are in 
two very different phases, according to the Life Cycle Theory, this poses certain challenges 
to the commercialization operation. One answer to these challenges fitting two very different 
dynamics in one company simultaneously, is offered in the Ambidexterity model. Usually 
ambidexterity is understood as a move by a company from a mature stage 
product/technology/solution s-curve to an emerging stage innovation s-curve within the 
same or neighbouring industries, in order to avoid declining with the old technology due to 
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the advent of new product/technology/solution innovations by competitors (Christensen, 
1997). This means acting in two s-curves simultaneously. 
In this case context, however, this more common, familiar and less demanding 
commercialization within the material (home) industry sphere had been analysed by the 
company but not chosen due to lack of a suitable business model, and hence the more 
demanding strategy of diversification to a completely different industry with completely 
different dynamics was adopted. The link between the business logics is that the company 
acts as a material producer in both industries. 
I have combined the two theories (Figure 2.5), Life Cycle Theory and Ambidexterity model, 
in a novel manner in order to contribute to market entry theories. In the figure, the move of 
the case company from one s-curve to another represents not two 
products/technologies/solutions in the same/neighbouring industries but two industries in 
different points of industry life cycle (mature and emergent) where the new venture is 
extending or diversifying the business of the parent MNC from one to another (home 
industry to target industry). The de alio entry strategy, the focus of this research, is marked 
in Figure 2.5. 
 
Figure 2.5. Entry strategy as key tool in diversification: adaptation of Life Cycle theory 
and Ambidexterity model 
At the same time, it is worthwhile to bear in mind that the driver behind the emergent stage 
of the target market and the attractive business opportunity is the possibility of a more typical 
industry wide switch from a traditional technology/solution s-curve to a new, disruptive s-
curve of the next generation solutions. 
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Furthermore, ambidexterity within home industry or neighbouring industries, as usually 
understood, is based on the activity of “disrupting” one’s own ongoing business in order to 
prevent others from doing it. According to the Ambidexterity model, this needs to be 
considered in the organizational structure of the new venture as well. In the de alio case 
context, the new product and venture do not directly disrupt the existing core business 
because the new venture operates in a completely different industry. Despite this, inside the 
parent company, the new venture may still compete for the same limited resources with the 
existing businesses and therefore an ambidextrous organizational structure approach is apt.  
According to the ambidexterity model, companies who have been successful in acting in the 
existing and new businesses simultaneously share the structure that separates their new units 
from the traditional ones allowing for different processes, structures and cultures while they 
maintain tight links between units by using integrated senior executive teams (O’Reilly & 
Tushman, 2004, p. 2).  
In the case context, the company wishes to diversify and expand into another industry, and 
hence does not want to exit, that is, sell the innovation (unlike many other innovators in the 
biotechnology industry). The parent has also considered the pros and cons of creating a spin-
off, which is an extremely common organizational structure in the biotechnology industry, 
as well as most of the competitors of their product are university spin-offs. However, as the 
company has decided that it prefers to foster new ventures that will one day be integral new 
business areas for the parent company, it has decided not to spin off.  
Therefore, the venture team in charge of the commercialization of the new product is 
structurally placed as an internal start-up within one of the departments of the parent 
company, with a common CEO steering all parent company internal start-ups. According to 
Klepper (2002), the venture may benefit of the accumulated knowledge, managerial and 
organizational experience, resources and capabilities of the parent company, while Dencker, 
Gruber & Sonali (2009), and Bayus & Agarwal (2007) add the ability to learn after entry. 
However, although being an incumbent in one industry is said to have these advantages (for 
example general business experience, knowledge, resources), the unit preparing the 
commercialization and market entry of a radical innovation is not being given these 
advantages automatically; instead, the unit was described as an “internal start-up” that so far 
had been successful enough to be given permission to continue the project but needed to 
continuously exercise “internal selling” and educating the parent company about the 
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activities. Moreover, considering a large multinational company, an incumbent in its home 
industry, may have very impressive strengths and assets to offer but it needs to be borne in 
mind that even the strongest asset in the home industry context may need to be fine-tuned or 
adapted to the target industry context in some degree in order to harness its full potential: 
a science-based business entails unique challenges that require different kinds of 
organizational and institutional arrangements and different approaches to 
management. Posed simply, what works well in other settings may not work as well 
in a science-based setting. (Pisano, 2006, p. 4) 
An array of further questions could be asked about the chosen internal start-up strategy and 
its repercussions. However, for the purposes of this research, these questions will be referred 
to ideas for further research. The focus of the research at hand will be in the market entry 
strategy and for this, the internal start-up structure shall be taken into account only from the 
point of view of how does it affect the entry strategy. 
2.2 Why to partner: Motivations for partnering in the de alio 
context 
I have now reviewed the classic and more recent market entry theories plus theories 
complementing the de alio and ambidexterity aspects of the case in order to cover the key 
factors of the case context related to partnering. It is now time to move on to discuss the 
needs, motivations, targets for partnering. 
As seen in the previous section, the triple novelty of the de alio context at hand means a new 
product and an unfamiliar, emergent market with a limited window of opportunity, which 
according to the theories mentioned, signify considerable demands to a company. Therefore, 
the entry strategy choice needs to provide tools to conquer those demands.  
Traditionally the full ownership and in-house activities (control) have been the default 
preferred option, and partnering viewed with the main motivation of mitigating risks when 
full ownership has been considered too risky. However, partnering has become ever more 
popular as a strategy in the fast-paced, complex reality of globalized business and especially 
high-technology markets. McCarthy et al agree, commenting that: 
Those firms competing in high-technology markets [...] will find themselves to be 
part of local and global networks. The strategic choices in this regard then are 
surprisingly simple: How to understand these networks in order to get them to work 
for you (or at least not against you), or ignore them at your peril. (McCarthy et al, 
2007, p. 246) 
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This means that partnering is expected and it may prove impossible to act in a partnering 
centred environment without adapting to its dynamics. 
2.2.1 Key motivations for partnering in home and target industry tradition 
From the literature review of the classic theories, I observed that mitigating risk has been the 
main motivation to partner in traditional manufacturing industries. This can be observed 
from the preference for full ownership, control and internalization of activities: partnering is 
considered the second best option (Dunning, 1995) which is chosen only in conditions of 
high uncertainty and little monopolistic advantage. Furthermore, contractual market 
transaction type of relationships is preferred over shared ownership partnerships. This also 
means that a motivation for partnering has been to exploit the firms existing competitive 
advantages in the risky conditions. 
From the literature review of the recent theories, on the other hand I observed that there are 
five key motivations categories which reflects that partnering is now used for many more 
purposes than in the traditional manufacturing industries.  
The first motivation category is still risk mitigation, especially in the target industry, that is 
biotechnology industry (Pisano, 2006; Furr et al., 2014), where partnering has become a key 
aspect of dynamics, a prerequisite for survival in an environment of enormous investments, 
risks and uncertainty. However according to Dunning (1995, p. 476), externalizing risk is 
perceived not only as sharing big investments, but long term trust-laden partnerships may 
contribute the advantages of full ownership (internalization) without the inflexibility, 
bureaucratic or risk related cost associated with it. Also, partnering for lower transaction 
costs or higher operating efficiency (R&D, manufacturing, marketing and distribution) or 
higher product quality may be seen as risk mitigation. Chesbrough & Schwartz (2007) agree 
with Dunning in saying that co-development alliances can greatly lower R&D cost and 
expand innovation output, while long term partnerships lower the risk as trust is built. 
The second motivation category is securing and obtaining assets. Greis et al. (1995) mentions 
securing assets related to research, development, manufacturing and marketing. Dunning 
(1995, p. 477) agrees and elaborates that partnering can be used to develop new skills, 
knowledge and other proprietary advantages, organize new knowledge, internalize the skills 
and learning experiences of other organizations and successfully manage a complex portfolio 
of core assets and value-creating disciplines. 
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The third motivation category is responding to barriers (Greis et al, 1995) and gaining access. 
Dunning (1995, p. 467, p. 475) mentions partnering to overcome or create barriers, gain 
access to new and complementary technologies, seek out and forge productive linkages with 
suppliers and customers. Chesbrough & Schwartz (2007, p. 56) agree, adding partnering to 
open up new markets that may otherwise have been inaccessible and discover new value 
creation opportunities previously unidentified. Powell (1998) adds gaining access to 
knowledge. Peng (2001, p. 812) agrees with Powell (1998) that possibility to learn from 
partners may be a tacit resource underlying a firm’s competitive advantage. 
The fourth motivation category is competition where partnerships can be used to position 
the firm in the competitive landscape of the industry and respond to global competitive 
environment through defensive or offensive partnerships. Greis et al. (1995, p. 615) 
exemplify partnership with a major competitor to gain joint global dominance as a defensive 
and a network of alliances to halt the perceived inroads of a major competitor as offensive. 
Powell (1998, p. 230) adds that firms with experience partners compete more effectively in 
high speed learning races. 
The fifth motivation category is time where Dunning (1995) argues that partnerships may be 
used to speed up innovatory or learning processes and upgrade the efficiency of particular 
activities, for example research and development (R&D). Chesbrough & Schwartz (2007) 
add that subsequent partnering agreements with long term partners tend to be faster and more 
profitable. 
The authors’ (Greis et al. 1995; Dunning, 1995; Chesbrough & Schwartz, 2007; 
Powell, 1998) views on partnering motivations can be combined and further classified as in 
Table 2.1. 
Table 2.1. Summary of partnering motivations in key theories 
Classification 
of partnering 
motivations 
Description 
Risk Flexible, less risky, less costly; allow many of the advantages of 
internalization without the inflexibility, bureaucratic or risk-related costs;  
externalize risk; lower transaction costs; upgrade the efficiency of 
particular activities - for example, research and development (R&D), 
marketing and distribution, manufacturing;  maintain and upgrade product 
quality; can significantly reduce R&D expense; expand innovation output; 
 23 
Faster and more profitable partnering projects enabled by aligning 
business models and sustaining and expanding long term partnerships. 
Assets Secure complementary assets (research, development, manufacturing, 
marketing): develop new skills; create and organize new knowledge, gain 
new proprietary advantages; internalize the skills and learning experiences 
of other organizations; successfully manage a complex portfolio of core 
assets and value-creating disciplines 
Barriers respond to barriers; overcome or create barriers; gain access to new and 
complementary technologies; seek out and forge productive linkages with 
suppliers and customers; open up new markets that may otherwise have 
been inaccessible; discover new value creation opportunities previously 
unidentified 
Competition respond to global competitive environment 
Time speed up innovatory or learning processes; upgrade the efficiency of 
particular activities - for example, research and development (R&D) 
2.2.2 De alio motivations for partnering in the target industry 
In the previous section, I identified the key motivations for partnering according to previous 
research. Of the recent theories reviewed in this study, Powell, Pisano and Greis et al. 
concern directly the biotechnology industry partnering dynamics. When a de alio newcomer 
enters the biotechnology industry market, all five aspects of partnering motivations (assets, 
competition, barriers, time, risk) are present. Hence, I will now deepen the meaning of these 
for a de alio in biotechnology industry in specific.  
In the following section, the interconnectedness of these motivations will be further clarified. 
To set the stage, Figure 2.6, depicts the key actors, partners and key roles of the networks 
involved in the dynamics according to the literature. 
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Figure 2.6. Key actors, partners and key roles of networks (Adapted from Pisano 2006, 
p. 81) 
Firstly, Pisano (2006, p. 7) lists profound and persistent uncertainty as one of the key features 
of biotechnology industry, which calls for mechanisms for managing and rewarding risk. 
Furr et al. agree with Pisano by listing the target industry as one of the most high-risk 
compared to other industries (Furr, Dyer & Christensen, 2014). For a de alio, the 
biotechnology then, is an especially risky industry to enter. A partner may also prove 
invaluable to diminish the heightened risks of a de alio entry. 
Secondly, in biotechnology, partnering has altered the nature of competition and hence the 
dense partnering networks itself may create a barrier to entry (Powell, 1998). Responding to 
barriers is an important motivation for a de alio, specifically in order to gain access to 
linkages with all the actors, customers, markets and opportunities.  
Thirdly, in the described competitive setting, de alio is a newcomer who needs to find its 
place in the competitive landscape and respond to competition. It needs to do it very fast as 
there is a lot to learn and the window of opportunity needs to be borne in mind. Furthermore, 
Pisano agrees with Powell who argues that in biotechnology, competition is best regarded as 
a learning race (Powell 1998, p. 228, p. 230) and firms with experienced partners compete 
more effectively in high speed learning races.  
Fourthly, this focuses the attention in the crucial time dimension, in other words, the fact 
that for a de alio entrant the time to learn is especially scarce. Pisano (2006, p. 7) also lists 
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the learning, and integration needs as typical to biotechnology industry. These are the rapid 
cadence of scientific progress which calls for mechanisms for cumulative learning, and the 
highly complex and heterogeneous scientific knowledge base which calls for mechanisms 
for integration across disciplines and functional areas of expertise.  
Fifth, hence, experienced partners are even more important: the entrant must be able to learn 
even faster than its competitors, as it starts out without the assets of knowledge, access and 
networks inherent to the competitors, such as the university spin-off start-ups that were born 
in the biotechnology industry. Instead, the assets need to be created, or adapted from the 
home industry to the target industry. Securing assets is especially important concerning 
complementary assets related to developing new skills, creating and organizing new 
knowledge and internalizing skills and learning experiences of the partner.  
One may add that Powell (1998)’s advice of not to focus too closely on the transactional 
details, but to promote the ability to do relational contracting, and maintain the relationships 
carefully, is especially useful for a de alio newcomer entrant. For de alio, developing target 
industry compatible capabilities of utilizing the obtained knowledge and maintaining 
relations and information flows (possession of capabilities for utilizing and building on new 
knowledge and developing relational capabilities and mechanisms through which 
information flows) stand out as especially important, since the home industry conventions 
and capabilities in partnering and using knowledge may not be directly applicable in the 
target industry. Similarly, networks, relationships and partnering arrangements may bear a 
different meaning and dynamic in the home and target industries. 
Consequently, these needs direct the choice of entry strategy towards the partnering modes, 
and the choice between different partnering modes and partner types.  
2.3 How to partner: Mode choice and maintaining partnerships  
In this section, I will review the classic and more recent theories from the point of view of 
how to partner in the case context. This includes firstly the entry mode choice and secondly 
the ways to execute and maintain partnerships in a successful manner. 
2.3.1 Mode choice and nature of partnerships in home industry tradition 
In the classic theories, internalization and full ownership and strong control related modes 
are in a key role to such extent that full ownership was considered the default option as 
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discussed in relation to partnering motivations other options were considered in situations 
involving too much risk for full ownership. In that case, contractual agreements were chosen. 
According to Dunning (1995, p. 464), most contractual arrangements were considered as 
market transactions and not partnering as such - even in situations in which there was some 
element of a continuing and information sharing relationship between the participants. 
Share and minority equity partnerships were non-preferred due to loss of control. Dunning 
argues that the traditional ideas of partnerships:  
viewed the boundary of a firm as the point at which its owners relinquished de jure 
control over resource harnessing and usage; and, to a large extent, this boundary 
was thought to be coincident with a loss of majority equity ownership. It is not 
surprising, then, that, for the most part, minority joint ventures were regarded as a 
second best alternative to full ownership. (Dunning 1995, p. 464) 
This reflects the locus of activity, resource use and innovation being inside the firm. 
The entry mode choices and explanations according to the major paradigms and theories are 
summarized in Table 2.2. The table shows clearly how the full ownership modes are the 
preferred and aimed at. The factors limiting ownership are low monopolistic advantages, 
high uncertainty and low transaction specificity of the assets or low internalization advantage. 
In these cases, contractual modes such as licensing and export modes are recommended. It 
is quite evident that joint ventures are considered marginal. 
Table 2.2. Classic theories of entry mode choice, adapted from Sharma 
and Erramilli (2004, p. 4) 
Paradigm Entry mode 
choice theory 
Explanatory 
constructs 
Entry mode choices 
and explanations 
Prominent 
studies 
Market 
imperfection 
paradigm 
Hymer’s Theory Monopolistic 
Advantage and 
degree of Market 
Imperfection 
Foreign direct investment 
(FDI) mode is chosen if 
the degree of Market 
Imperfection is high. 
Otherwise, licensing is 
chosen 
Hymer (1976); 
Buckley and 
Casson (1976); 
Teece (1980) 
IPLC Theory Life Cycle Stage 
of the Product 
Export mode is chosen in 
the earliest stage and FDI 
mode is chosen during the 
later stages 
Vermon (1966); 
Poh (1987) 
Behavioral 
Paradigm  
Internationalization 
Theory 
Market 
commitment and 
The firm enters into a 
target country through 
indirect exporting and 
Johanson, J & 
Wiedersheim-
Paul (1975); 
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Market 
Uncertainty 
gradually switches over 
exporting through 
independent 
representatives, sales 
subsidiary and wholly 
owned subsidiary mode 
with the reduction of its 
market uncertainty 
Johanson and 
Vahlne (1977); 
Johanson (1990) 
Market 
Failure 
Paradigm 
Internationalization 
theory 
Firm-specific 
knowledge and 
the degree of 
Market Failure 
FDI mode is chosen if the 
degree of market failure is 
high. Otherwise, licensing 
is chosen. Joint venture 
and export modes are also 
explained by the modified 
framework 
Buckley and 
Casson(1976, 
1998); Buckley 
(1988); Hennart 
(1986); Hennart 
and Park (1993); 
Chen and 
Hennart (2002) 
Transaction Cost 
Theory 
Degree of 
Transaction 
Specificity of an 
asset 
Higher control mode is 
chosen if the degree of 
transaction-specificity of 
an asset if high. 
Otherwise, a lower control 
mode is chosen 
Anderson and 
Gatignon 
(1986); 
Anderson and 
Coughlan 
(1987); Coase 
(1937); Klein, 
Frazier and Roth 
(1990); Erramilli 
and Rao (1993) 
Eclectic theory Ownership-
Advantage (O), 
Location-
Advantage (L), 
and 
Internalization- 
Advantage (I)  
Export mode is chosen if 
‘L’ favors home market. 
FDI mode is chosen if ‘L’ 
favors target market and 
the ‘I’ is higher. Licensing 
mode is chosen if ‘L’ 
favors target market but 
the ‘I’ is low. Joint venture 
mode is chosen under 
partial market failure 
conditions 
Agarwal and 
Ramaswami 
(1992); 
Brouthers and 
Werner (1996); 
Dunning (1980); 
Dunning (1995)  
 
In the classic theories, the level of control is the most important factor and modes are 
classified and chosen based on that. The second important factor is the location of activities. 
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The most important activities are considered to be production and marketing.  Classification 
by ownership and location can be seen in Figure 2.7. This reflects the highlighted importance 
of ownership, location and production and marketing activities in the classic theories – and 
the traditional manufacturing industries that gave rise to these theories. Later in this study, I 
will discuss the relationship with the empirical findings on the case company preferences. 
 
Figure 2.7. Categorization of entry modes by ownership and location.  
Adapted from Sharma and Erramilli (2004, p. 3). 
2.3.2 Mode choice and nature of partnerships in target industry tradition 
The complete change of perspective, preferences and meanings of partnering taking place in 
the business logics is visible in the recent theories. Partnering modes are in a key role and 
the mode choice is based on a wide array of modes utilized simultaneously in order to create 
a varied and heterogeneous portfolio of collaborations. Also, even contractual transactions 
now include a more collaborative atmosphere than before and may include aligning business 
models (Powell, 1998).  
 29 
On the other hand, ownership is no longer considered necessary in order to extract the 
benefits of an asset (Powell, 1998). However, although partnering is considered the default 
option, in the case of core competitive advantages full ownership is necessary. Chesbrough 
& Schwartz (2007, p. 57) advice companies to carefully classify their capabilities into core, 
critical and contextual and partner accordingly. Core capabilities refer to the key sources of 
company’s distinctive advantages and with them in-house R&D is best. Critical capabilities 
are vital to the success of the complete product or service offering in the market, but are not 
core capabilities of the firm. In this sphere, partnering should happen on a win-win basis, 
which means aligning business models so that when one partner executes their model well, 
the other benefits and vice versa. Contextual capabilities are needed to complete the offering 
but provide little of the differentiation or added value and hence the company should switch 
to another partner if one is not performing. Chesbrough & Schwartz (2007) argue that critical 
capabilities partnerships bring the most added value, while companies usually should not 
partner at all on their core capabilities or the partnering would have very special conditions. 
Dunning (1995) agrees stating that on existing competitive advantages inter-firm 
cooperative arrangements should be controlled. 
The risks are also perceived differently in the recent theories. Dunning argues that partnering 
is usually considered as a trade-off between losing part of the control in order to gain the 
perceived benefits of partnering. Nevertheless, the risks involved in losing part of the control 
are balanced by engaging in relationships “based upon a commitment, on the part of each 
party, to advance the interests of the alliance; and upon mutual trust, reciprocity and 
forbearance between the partners” (Dunning 1995, p. 470). Furthermore, in the recent 
theories, full ownership is considered a risky option, while in a long-term, trust-laden 
partnership the companies can enjoy many of the benefits of in-house modes without the risk, 
bureaucracy and other in-house disadvantages. In networks of this kind, there is an extra 
advantage for the companies operating as network moderators, as they get to enjoy the 
advantages of arbitraging complementary added value activities. These are the 
(quasi-) internalization (I) related advantages of alliances identified by Dunning (1995). 
Furthermore, the mode corresponding to the asset-seeking partnering motivation may be 
R&D collaboration, or other cooperative venture mode. Similarly, according to Dunning, the 
mode corresponding to the overcoming barriers (access) partnering motivation may be 
foreign direct investment (FDI), minority owned joint venture or non-equity arrangements 
that are intended to gain speedy entry intro unchartered and unfamiliar territories. Also, the 
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mode corresponding to the time dimension of partnering motivations is cooperative ventures 
when aiming at speeding up innovations; and minority joint venture or non-equity 
arrangements when the motivation is a fast market entry (Dunning 1995, p. 469).   
However, Powell (1998) and Pisano (2006, p. 162) point out that the benefits of partnering 
are not automatic nor results only from the mode choice or contractual conditions. They 
remind that the benefits depend on partnering capabilities of each of the partners and of the 
execution of the partnership project. Writing on business development deals such as alliances, 
licensing agreements and partnerships, Pisano states that:  
doing a deal signals potential; whether value will ultimately be created depends on 
the execution of the project. Deals alone can never create value. They can only (if 
properly structured) unlock value that exists and enable value capture. [...] 
Ultimately, value creation and capture are what matters. Pisano (2006, p. 162) 
Similarly, according to Powell (1998), biotechnology companies need both experienced 
partners and the ability to absorb knowledge in order to succeed in the competition which is 
best regarded as a high speed learning race. In my interpretation, this practically emphasizes 
that access to knowledge is of little use, if the company does not know how to absorb 
knowledge or how to utilize it. Peng (2001, p. 812) agrees with Powell (1998) that 
capabilities to learn from partners may be a tacit resource underlying a firm’s competitive 
advantage. Powell (1998, p. 233) calls developing these capabilities “learning how to learn”, 
and emphasizes that it is crucial for companies both large and small to learn from 
collaborations and construct a portfolio of collaborators that provides access to both the 
emerging science and technology and the necessary organizational capabilities. This is 
considered so important that most biotechnology companies have individuals working as 
network managers (Powell, 1998). Moreover, according to Powell (1998), the varied 
portfolio is better, as “Heterogeneity and interdependence are greater spurs to collective 
action than homogeneity and discipline” (Powell 1998, p. 238). Powell (1998, p. 231) 
maintains that a firm’s portfolio of collaborations is a resource, an important part of a firm’s 
value and a signal to markets, as well as to other potential partners, of the quality of the 
firm’s activities and products, because nowadays in high-technology innovation centred 
industries such as biotechnology, innovation happens in networks of learning, rather than 
individual firms. This ability to absorb knowledge encompasses two parallel and equally 
necessary kinds of learning goals. Firstly, learning from collaborations and secondly, 
learning how to collaborate.  
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Considering first the learning from collaborations, Powell (1998, p. 236) emphasizes that it 
requires both of the two aspects a) access to knowledge and b) possession of capabilities for 
utilizing and building on such knowledge. According to Powell (1998, p. 231), the capability 
building is a two-way dynamic: internal capability is indispensable in evaluating the ideas 
or skills developed externally in the network, and on the other hand, the network serves for 
testing the internal expertise and learning capabilities. 
Then considering the second aspect, in order to learn how to collaborate in a given context, 
it is important to balance both of the principal foci of the collaboration theory field. 
According to Powell (1998, p. 229), the first one is contractual, that is, transaction, 
negotiation and mutual exchange of rights. This includes considerations whether common 
assets are being pooled or different resources traded, which party retains what control rights, 
what stage of development a project is at, and whether some form of ownership is involved. 
The second focal point is processual, that is, developing relational capabilities and 
mechanisms through which information flows. This includes continuous communication and 
organizational learning, extent to which the collaboration is embedded in multiple ongoing 
relationships and the emergence and deepening of the relational capability of organizations 
over time. 
The contractual focus is more linked with the classic points of view on partnering and entry 
modes which depicts the how to collaborate as an event or choice, while the processual focus 
is more recent in the market entry literature as well. As Powell (1998, p. 229) speaks of the 
general condition of the collaboration, he warns that focusing too closely on the transactional 
details risks “missing the boat”: the ability to do relational contracting, and the process of 
maintaining a relationship matters. In a similar vein, Dunning (1995, pp. 468-470) notes that 
since the 1980s, the great majority of inter-firm associations have tended to be less formal 
in structure and are more likely to rest on a consensus of agreement between the participants 
based upon a commitment of each to advance the interests of the alliance and upon mutual 
trust, reciprocity and forbearance between the partners. Extending Powell’s argument, one 
may say that seeking a partnership, companies often concentrate too much on simply 
obtaining access to knowledge via conducting successfully the contractual aspect. However, 
that is only the starting point for the partnership and does not in itself guarantee the 
continuation of a successful learning curve.  
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Furthermore, certain types of partnering dynamics are typical especially in the target market, 
that is, biotechnology industry, and perhaps not so prominent in other industries, such as the 
home market (that is material industry) of the case company. One of these dynamics is the 
deeper and more multifaceted meaning of networks. 
After having reviewed the theories on motivations and ways of partnering, in order to reflect 
the multifaceted nature of networking and partnering in the target industry, in the following 
Table 2.3, I will bring the motivations and processual ways of partnering together with the 
three key dimensions of the recent market entry theories, from the point of view of partnering 
and networks. The updated version of Dunning’s eclectic theory (1995), is used as the basis, 
complemented by inputs from other, even more recent authors. This summarizing adaptation 
of also shows the compiled ways of using the partnership portfolio suggested by Powell 
(1998) to obtain competitive advantages, which in turn can be utilized to create and capture 
value. This compilation and extension shows clearly the processual nature of market entry 
into innovation centred industry such as biotechnology: the entry is much more than mode 
choice or a one-time event.  
Table 2.3. Why and how to partner: summarizing adaptation of the eclectic theory and 
other recent theories 
Intangible assets 
(ownership-related, O) 
Dimension Author 
Knowledge of how to create 
partnerships in the target 
market 
Articulating the business 
model, understanding others’ 
business models, aligning 
business models with partner 
Chesbrough & Schwartz 
(2007) 
Assessing own and others’ 
capabilities and classifying: 
core, critical, contextual 
Knowledge of how to 
maintain partnerships in the 
target market 
Network managers Powell (1998) 
Aligning business models, 
building trust, synergies, 
Common goals 
Chesbrough & Schwartz 
(2007) 
Subsequent partnership 
projects 
Capability to learn from 
partnering 
Accessing to knowledge Powell (1998); 
Dunning (1995) Ability to absorb, create, 
organize, disseminate, 
leverage and level knowledge 
in the organization 
Internal capability to evaluate 
ideas and skills developed 
externally 
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Ability to use the network to 
test the internal learning 
capability and expertise 
Capability to learn how to 
partner 
Contractual: Industry 
conventions on transactions, 
IPR, negotiations 
Powell (1998) 
Processual: Industry 
conventions on relational 
contracting, mechanisms 
through which information 
flows, building synergies and 
trust 
Partnership portfolio  as a resource, providing 
access to both science and 
organizational capabilities  
Powell (1998) 
as a signal to markets and 
partners 
Network moderator role Dimension advantages of 
orchestrating and arbitraging 
complementary added value 
activities  
Dunning (1995);  
Powell (1998) 
Location specific variables 
(L) 
Dimension Author 
 
Interplay of local, national, 
regional, international and 
global 
 Dunning (1995); 
Maine (2014) 
Cluster advantages  Strong and balanced ecology 
of research centres, talented 
human resources, excellent 
transportation, communication 
and other assets supporting 
innovation 
Dunning (1995); 
Maine (2014); 
Phene & Tallman (2012) 
Distributor and parent 
company multinationality 
related advantages 
 
Operational flexibility, more 
opportunities for arbitraging, 
production shifting and global 
sourcing, knowledge about 
international markets, taking 
advantage of geographic 
differences 
Dunning (1995) 
Quasi-internalization 
(I, internalization related) 
 
Dimension Author 
Trust, forbearances, 
reciprocity and consensus 
advantages 
 
Long term partnerships with 
subsequence, increasingly 
profitable partnership projects  
Chesbrough & Schwartz 
(2007) 
 
Avoidance of search and 
negotiating costs, costs of 
moral hazard, broken 
contracts and protecting the 
reputation of the firm  
Dunning (1995) 
Substituting direct 
investments with partnering 
 
Advantages of internalization 
without the inflexibility, 
Dunning (1995) 
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bureaucratic or risk-related 
costs  
Moderator role  Advantages of orchestrating 
and arbitraging of 
complementary value-added 
activities  
 
Dunning (1995);  
Powell (1998) 
 
2.4 Theoretical framework 
In this literature review chapter, I have reviewed existing relevant theories and concepts on 
partnering and extended them as necessary. I have presented the key aspects (control and 
ownership meaning internalization, ownership-specific assets, locations) of the classic 
theories that correspond to the case company home market dynamics of traditional 
manufacturing and their reinterpretations in the more recent theory updates which 
correspond to the target market dynamics of partnering and innovation centeredness. 
Furthermore, I have combined the de alio diversification, industry life cycle and 
ambidexterity theories in a novel way and used this model to complement the market entry 
and partnering theories in order to cover the case context key aspects.  
Moreover, I have presented the motivations for partnering in the classic and more recent 
theories by classifying them in five key categories: a) using, securing and obtaining assets, 
b) mitigating risk, c) responding to barriers and gaining access, d) time or speeding up and 
e) responding to competition. These were reviewed specially from the point of view of de 
alio entry to biotechnology industry.   
Last, I reviewed the literature from the point of view of how to partner. This included two 
aspects. Firstly, the mode preferences presented in the classic and more recent theories and 
second, the processual ways and dynamics of conducting and maintaining partnerships in 
each set of theories.  
Figure 2.8 combines the theories discussed so far from the point of view of why de alio needs 
to partner in this context and what are the partnering motivations and targets. De alio market 
entry factors are depicted in the first line. Combining the above mentioned contributions of 
Dunning, Greis et al., Chesbrough & Schwartz, Pisano and Powell, the partnering needs, 
desired benefits and motivations are depicted in the second line. Furthermore, the targets 
derived from the motivation theories and the biotechnology industry context specific theories 
are depicted in the third line of the graph. 
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Figure 2.8. Summary of key theories on partnering needs, motivations and targets 
In other words, in order to succeed in the de alio context, the company needs to secure critical 
assets, overcome barriers to access, and position itself in the competitive landscape to gain 
a foothold against the competitors endemic to the target market. Furthermore, considering 
the limited window of opportunity, in-house capability development as a response to these 
needs is too slow if at all possible. Partnering is needed to reach the goals that are not 
reachable alone/ in-house and partnering is a way to respond to all the above mentioned 
needs.  
The theoretical literature analysed in the review creates an interesting starting point in the 
light of which to examine the entry strategy choice in the case context. Derived from the 
theories and case characteristics mentioned above, the theoretical framework of 
conceptualizing the commercialization, market entry and partnering strategy process is 
summarized in Figure 2.9. The case context is the starting point, from which the context-
specific partnering needs stem. The needs are elaborated into motivations and targets for 
partnering. Then, the motivations and targets guide the choice of suitable modes and ways 
to partner. The partnerships together force a heterogeneous portfolio with different 
combinations of why, how and with whom to partner. The portfolio is then used both as a 
resource and as a signal to the others in order to obtain competitive advantages, to create and 
capture value. As the company establishes itself in the new industry, the context changes and 
therefore the needs also change, which means that the partnering decisions need to be revised 
at constant intervals, using the proposed partnering framework.  
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Figure 2.9. Theoretical framework on the partnering processes  
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3. METHODOLOGY 
In this chapter, the general and specific research methods, materials and ethical 
considerations forming the basis of this study are discussed. 
3.1 Qualitative research method 
The chosen methodology to complement and correspond to the above mentioned theoretical 
framework and research context in the Thesis is qualitative research. This is because the 
main research problem asks how can companies manage the challenges of de alio market 
entry by forging partnerships, and the research questions focus on with whom, why and how 
to partner in the case context. This point of view indicates a processual and interpretive 
perspective, to which qualitative research methods are suitable (Eriksson & Kovalainen 2008, 
120).  
While considering the methods, the reader is also advised to take into consideration the 
distance factor of qualitative research methods, that is, in order to reach high quality results, 
the researcher needs to diminish the distance with the participants (as opposed to quantitative 
research). According to Eriksson and Kovalainen (2008, 57), there are three factors to be 
considered. First, that participants are the best experts; second, the aim is to include the 
participant’s voice; and third, the researcher is the primary instrument whose language, 
cultural and individual characteristics form a lens through which the research process is 
mediated to the audience. 
3.1.1 Single intensive case study  
The conceptual implications of the research context and research questions suggest that the 
specific qualitative research method type appropriate for the research is case study. This is 
because the case study emphasizes detailed and holistic knowledge of a phenomenon and is 
based on multiple empirical sources rich in context (Eriksson & Kovalainen 2008, p. 117). 
Furthermore, of the various different case study methods, single, intensive type of case study 
is best for understanding the process of formulating the market entry strategy and choosing 
an entry mode in a very specific context. This permits studying the case more in depth than 
with multiple cases, learn how a specific case works and analyse whether or not it is unique, 
critical or extreme (Eriksson & Kovalainen 2008, pp. 120-121). The case study also implies 
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that the case has a beginning and an end, or, boundaries (Eriksson & Kovalainen 2008, p. 
117). The boundaries of this case were drawn from the case company meeting with the 
research project team in November 2015 when the market entry investigation started and the 
formulation of the market entry strategy began. The end of the research timeframe is placed 
in September 2016 when the research project data collection was finalized. Secondary 
materials were included from the time immediately preceding and during the project, for 
example market analysis reports, media and background materials from the company. The 
focus is a strategy viewpoint which draws the scope boundary of the case. 
The single case also provides the opportunity to present a case that motivates further research 
by offering information that may help to complement or sharpen the existing theories in the 
field, or inspire the further research of a field relatively little studied (Siggelkow, 2007, p. 
21). In this context, that means multinational companies entering de alio (diversifying) to 
the biotechnology or other partnering centred industries, or in more general terms, the triple 
novelty of multinational companies commercializing a new innovative product in an 
unfamiliar, emerging market. A further advantage of this type of study is that it illustrates 
the real-life dimension of the phenomenon studied and helps to keep theory grounded with 
a real-life situation (Siggelkow, 2007, p. 21), putting the case itself in the centre of the 
research (Eriksson & Kovalainen 2008, p. 121).  
Considering the alternatives, creating a comparative set-up or embark on an 
extensive/multiple case study (Eriksson & Kovalainen, 118, pp. 122-123) proved 
complicated, as other potential companies in the same context were not available. This was 
due to the fact that an MNC attempting a de alio (diversifying) entry to an emergent market 
by commercializing a new innovative product in an unfamiliar, non-neighbouring industry 
with very different business logic, represents a somewhat extreme and unique case. On the 
other hand, a comparative case study of two or more very different kinds of firms with 
different approaches to market entry to biotechnology industry would be very interesting but 
proved too large a research endeavour for a Master’s thesis. However, this indicates possible 
avenues for further research in the area. 
3.1.2 Semi-structured interviews 
The qualitative research method chosen to produce the primary data for the case study 
research is interview, complemented by the secondary data of company documentation, 
media and social network analysis (McCarthy et al, 2007) to produce a balanced view of the 
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commercialization process studied. In addition, interviews were also used to focus the 
research: the research process was started by reviewing literature based on the preliminary 
research problem statement, which was commercialization strategies for new products in 
biotechnology, in situations which involve the creation of a new market. Furthermore, in the 
two preliminary focusing interviews and group discussions with the company representatives, 
the researcher could further specify the problem statement, and focus it on partnering. 
The research questions and context of the given case require the use of interviews for mainly 
two reasons (Eriksson & Kovalainen 2008, pp. 80-81): firstly, for collecting information that 
is not available in a published form and secondly, the aim is to collect the interviewees’ 
experiences and viewpoints on the process. In order to instil this information, I consider 
semi-structured interviews the most appropriate method for the task (compared to structured 
or unstructured ones). This is because they can be utilized for both “what” and “how” types 
of questions and produce systematic and comprehensive information for the use of content 
analysis, yet leaving room for items that arise from the informant’s experience and interview 
situation (Eriksson & Kovalainen 2008, 82-83).  
However, interviews as a source of data imply the possibility of bias as the interviewed 
individuals may tend to rationalize the activities afterwards, or exaggerate their own 
contribution. This risk was diminished by interviews being conducted while the decision-
making process unfolded, not only afterwards. Furthermore, analysing also the secondary 
data (that is, company documentation, media and social network analysis data produced 
during the strategy process) should balance the risks of the first kind. Interviewing a 
sufficient sample of persons ought to balance the risk of the second kind by utilizing data 
from various sources. 
3.1.3 Content analysis 
The data analysis was carried out by using content analysis, which focuses on themes and 
patterns across the data (Eriksson & Kovalainen 2008, 187-188), hence helping to answer 
the questions of how can companies manage the challenges of de alio market entry by forging 
partnerships, and with whom, why and how to partner in the case context. The content 
analysis involves a coding system developed from the basis of the material itself (as a 
contrast with pre-planned coding; Eriksson and Kovalainen 2008, 129). The specifics of how 
the data analysis was carried out by using content analysis is further discussed in Section 
3.2.4. 
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3.2 Data sampling, collection and analysis methods 
In the following subsections, the methods of data sampling, data collection and data analysis 
of research at hand are discussed in detail. 
3.2.1 Research context implications 
The context of this study is manifold: 1) MNC 2) material manufacturing firm 3) entering 
de alio into another, non-neighbouring industry 4) in a segment of the biotechnology industry 
5) in an emergent phase of the life cycle 6) with a new innovative product. The context of 
the research requires the researcher and the reader to consider its scope and implications. As 
stated earlier, the research aims to be of use especially for the team working with the 
innovation and the MNC management making decisions about market entry strategies. 
Hence, the strategy approach will be adopted in the research. For this reason, many other 
points of view shall remain outside the scope of the research but indicate possible avenues 
for future research. 
The context of a manufacturing firm implies that the results may not be applicable to service 
firms. In the same manner, the findings related to the biotechnology market may or may not 
be generalizable to other markets, and comparing these lies outside the scope of this study. 
Furthermore, this research concentrates on the choices of a MNC, which means that the 
results will not be directly applicable to a smaller firm or a less internationalized one, whose 
resources are of different size and type. 
3.2.2 Sample 
Apart from scientific articles and general background material, the case material of the 
research includes primary data and secondary data.  
The primary data is in the form of material produced specifically for the purposes of this 
research, that is, interviews. In order to identify the interview sample, the snowballing 
method was used in order to find hidden populations in a context where the sample size and 
boundaries were hard to define: an emerging fragmented market segment and complex 
context, which, furthermore, required several kinds of informants. As no public sources exist 
about who are the members of the network or group, the interviewees involved in the 
dynamic were used as informants to express who else could provide the researcher with the 
necessary material. Hence, the research group identified the first interviewees, who 
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introduced the second group who introduced the third group until saturation. Limitations of 
the method may arise due to choice of initial interviewees and possible biased sample, as 
interviewees’ choice of next interviewees is limited to those they know and whom they wish 
to recommend due to their respective reasons. These limitations can be alleviated by 
choosing a diverse initial sample. (Morgan, 2008; Heckathorn, 1997; Erickson 1979).  
In other words, three factors guided the choice of interviewees: Firstly, the snowballing 
method, secondly, because the individuals are members of different parts of a specific 
network and thirdly, they participate in certain processes. More specifically about the nature 
of the interviewees: one third of the interviewees are women (8/24), the interviewees 
represent different ages from young to senior and various European cultures and nationalities. 
All in all, six interviews were conducted in English and the rest in Finnish. The occupational 
backgrounds of the interviewees include managerial and other positions in the case company 
(11/24), other companies of the target industry (8/24) and universities (5/24). Also, their field 
of specialization varies from natural sciences to engineering and business. The detailed list 
concerning the profile of the interviewees is not included here due to issues of anonymity 
and recognisability which are further discussed in Section 3.2.5. 
The secondary data, on the other hand, consists of various sources. Documentation was 
provided by the case company during the process (such as strategy documents, market 
analysis reports, white papers and meeting notes). Furthermore, press releases and media 
coverage were available but scarce, as the commercialization of the innovation was not made 
public until sometime into the project. For the social network analysis, data was collected 
from the materials of an international conference on the target market segment and from 
public online sources.  
The secondary data (strategy documents, meeting notes and press releases) were chosen 
according to their ability to provide information about how can the company manage the 
challenges of de alio market entry by forging partnerships and with whom, why and how to 
partner in the case context. Online coverage (in Finnish and English) was searched using as 
search terms the case company name, product name, and industry name. For the social 
network analysis purposes, online data was searched using the names of the organizations in 
question. 
The limitations of data included that due to confidentiality issues, the researcher was not 
granted access to data identifying the partners and networks of the case company in the target 
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industry. Furthermore, for the same reasons, the case company did not grant interview access 
to their customers nor partners, which causes the researcher to render these aspects as 
suggestions for further research. Similarly, there was no access to emails nor actual company 
meetings or situations for observation. Nevertheless, lesser-scale, secondary observation was 
made during interviews, meetings and one full day workshop of the research team with 
company representatives. 
What comes to the ethical aspects of the data sample, in order to answer the research 
questions properly and to construct a case study, close cooperation with the case firm was 
necessary to gain access to first-hand material and various types of data. In this context, it is 
due to inform the reader that in order to render the research possible, during the Thesis 
research process, I worked as Research Expert for an Aalto University research project which 
included a remuneration. I will further discuss the ethical considerations of the study in the 
section 3.2.5. 
3.2.3 Data collection 
Furthermore, the data collection of interviews and documentation was done in the following 
way. In the project, we conducted altogether 25 interviews in Finnish or English between 
December 2015 and June 2016. Each informant was interviewed once (except for one 
informant who was interviewed both in the early and the late stage of the project). 
The interview length varies between approximately 45 and 90 minutes. The majority of the 
interviews took place face to face, the minority via telephone or Skype. In the interviews, 
between one to three research team members and one informant were present at a time. 
Furthermore, the interviews took place in meeting rooms and similar spaces at the case 
company and other organizations (except for one interview in a home setting). We also 
recorded one group discussion between the research team and company representatives as 
this formed an informal group “interview” where all participants could ask each other 
questions. In the group situation, a PowerPoint presentation functioned as a thematic outline 
and stimulus material. Furthermore, one full day workshop was organized with the company 
team, but was not recorded. The interviews and the group discussion were recorded and 
transcribed for analysis, using the word-for-word -method, as the more detailed method 
intended for discourse analysis (Eriksson & Kovalainen 2008, p. 85) was not necessary. 
Observations and notes were made during the recordings concerning the non-auditive 
behaviour of informants.  
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On the other hand, secondary data was collected from various sources. Company internal 
documentation was received from case company and public documentation was obtained via 
internet. Media coverage was collected by accessing internet. Network analysis data was 
obtained by research team members participating the target industry conference and 
combining it with internet sources. 
What comes to keeping the research material and data, the full set of interview recordings is 
kept by the research project. A copy of part of the recordings package, as well as transcribed 
interviews, documentation collected from public sources and company internal sources are 
kept by the researcher. 
3.2.4 Data analysis 
In the first phase of the data analysis, the primary information was organized into a case 
record with the help of a software, electronic and paper files to collect all empirical data 
together into a package (Eriksson & Kovalainen 2008, p. 126). The package was organized 
following a thematic logic derived from the research questions asking with whom, why and 
how to partner in de alio context.  
As the chosen analysis method is content analysis, the following analysis phase was coding, 
for which a data-driven coding system was developed from the empirical data collected (as 
opposed to pre-planned coding systems). This inductive-oriented strategy allows the 
researcher to more directly interpret the themes and patterns extracted from the material 
(Eriksson & Kovalainen 2008, 129). The practical work was carried out using the software 
named Atlas.ti 7. 
In the next phase, the resulting codes were further grouped and organized to find patterns in 
the data set and to construct themes. The relations of the themes to each other were then 
analysed. The themes most central to the research questions were identified and the 
justifications for this choice were documented. The most central themes were then 
interpreted in the light of identifying the key partners, needs, motivations and corresponding 
possible modes for partnering, along with the processual view of how to partner and maintain 
partnerships.  
Furthermore, comparisons of views presented by different actors in the case context were 
made with the help of organizing the data into tables and figures, in order to highlight the 
key aspects, similarities and differences. Also, the primary data views were compared with 
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those expressed in the existing literature. Then, conclusions were made of the significance 
and meaning of these similarities and differences. 
On the other hand, the data collected for the purposes of social network analysis was 
organized using spreadsheets and then visualized and analysed using the software named 
Gephi 0.9.1.  
Subsequently, the results and conclusions of the data analysis were compared with the 
existing theoretical knowledge and frameworks of partnering, market entry strategy and 
entry mode choice, plus complementary theories mentioned in the literature review in 
chapter 2. This was done in order to conclude if this case supports or challenges the existing 
theories about partnering and choosing the entry strategy, in which aspects and why. Finally, 
suggestions for future research were made and managerial implications explicated according 
to the insights of this analysis. 
3.2.5 Ethical considerations 
Conducting research involves an array of ethical issues, varying in each study according to 
the setting. In the following, I will discuss the ethical considerations involved in this study, 
such as informed consent, anonymity, confidentiality, relationship and distance with the 
researched, and sponsorship. 
Firstly, informed consent was obtained from each interviewee in connection with the 
invitation to participate and again in the beginning of each interview. As suggested by 
Eriksson & Kovalainen (2008, p. 71) basic information of the study, such as the purpose, 
recordings, basic procedures, roles and identities of the research team, the university and the 
sponsoring company, the use and future use of the data, anonymity and voluntary 
participation were made available in connection with asking for the consent.  
Secondly, anonymity of both the informants and the case company needed to be upheld in 
the study. Anonymity means keeping the identity of the participant hidden, but different 
variations in the degree of anonymity exist (Eriksson& Kovalainen, 2008, p. 73, p. 302). In 
this study, personal information and the identity of the informants have been carefully 
withheld both during the research process (in all communications such as live conversations 
and textual exchanges) and in this research report. Identity details have not been marked 
where it is not absolutely necessary. Furthermore, in the project, the identities and research 
records of the participants have been stored in files to which no unauthorized access is 
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possible due to utilizing electronic accounts with usernames and passwords, and locked 
physical locations. 
An obvious exception to the anonymity rule have been the group conversations, meetings 
and the workshop, in which the participants have all been employees of the case company 
and aware and consenting of the non-anonymity of the exchanges during these events, due 
to receiving previous information via email. They have also identified themselves to the 
other participants in the beginning of the conversations. However, the identities of the 
participants have only been known to the other participants of the same event and have not 
been disclosed to other persons. 
In the research report, I have upheld the anonymity of the informants by using various 
techniques. To start with, I have disclosed the profiling details of the informants (in the 
Sample and Data Collection sections, chapter three of this report) only to the extent necessary 
for the reader to be able to assess properly the nature and extent of the data sample of the 
research. I have prioritized anonymity in those cases where these two principles needed to 
be reconciled. In general, the information of who was interviewed (not even the mere list of 
informants) for the study was not disclosed to anyone outside the university research team 
and the interview recordings literation company employees, bound by confidentiality 
agreements. 
Moreover, I have screened beforehand the information to be disclosed in this report and other 
exchanges in order not to reveal details or combinations of details which could jeopardise 
the anonymity of an informant. This was especially important in order not to violate the trust 
relationship or cause difficult situations for informants presenting critical views (Eriksson& 
Kovalainen 2008, p. 66) while the research was conducted in coordination with the 
management of the company.  
Furthermore, in the report I have used pseudonyms such as “interviewee A” of the informants 
and “Department A” of their place in the organization. Other types of pseudonyms such as 
invented names would have offered other advantages such as a less distanced, real-life feel 
and may have been easier to remember for the reader. However, I chose to use alphabetical 
letters due to the fact that pseudonym names tend to provoke interpretations by the reader, 
such as the gender or ethnical identity of the informant. For example, the female gender 
represented only one third of the sample and it became obvious that by combining the gender 
information with the information disclosed in the report would have made it possible for 
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certain readers within the sample to identify other participants. The same applies to ethnical 
groups that represent for example only one quarter of the sample. In the case of female 
informants of such an ethnical group, the dilemma of name pseudonyms would be even more 
obvious. Also, I did not consider using names of the other gender or other cultural/ethnical 
groups a viable option, as they would have given the reader a distorted view of the data. 
On the other hand, the anonymity of the case company was upheld in the research report by 
utilizing terms such as “case company”, “parent company”, “venture” and “department A” 
instead of the real company and department names, and the more general terms “target 
market” “target industry”, “biotechnology industry”, “home market”, “home industry” and 
“material manufacturing industry” instead of the exact market segment names. Furthermore, 
in the social network analysis, the names of network participants were replaced by numbers 
and letters functioning as pseudonyms. I considered that this anonymity was possible to 
achieve without causing distortion or difficulty for the reader while presenting the case 
study.   
Thirdly, in qualitative research, it is often necessary to diminish the distance between the 
researcher and the researched in order to provide high quality results, yet there a various 
possible levels of distance when it comes to the relationship between me as the researcher, 
and the researched (Eriksson& Kovalainen 2008, p. 57, p. 65). The study required getting 
involved for example by acting as a facilitator in the processes taking place in the workshop. 
However, during the whole research process, I decided to withdraw in those occasions where 
the role of facilitator could have turned into active participation in the decision-making or 
providing answers to business problems when it was clear that the answers and decisions 
need to come from the researched. Similarly, the distance between researcher and researched 
was diminished when engaging in interviews, or case company meetings and the workshop. 
However, I did not work or otherwise spend prolonged periods of time with the researched 
and the methods did not include observation or participation as such. 
Fourthly, in order to render the research possible by obtaining access to the case data, I 
participated in a university research project which included a remuneration from the 
university. The case company was sponsoring the project but did not attempt to affect 
(Eriksson & Kovalainen, 2008, p. 66) my research plan or methods apart from requiring that 
the case company remain anonymous. Due to confidentiality issues such as confidentiality 
agreements with partners, not all company data was accessible, as discussed in the Sample 
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section of this chapter. A company employee conducting similar research might have had 
access to the data mentioned, yet this would have created a different kind of research setting 
and relationship with the researched, with other kinds of ethical issues to be considered.  
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4. ANALYSIS OF EMPIRICAL FINDINGS 
In this chapter, the case context, home and target industries as well as the de alio company 
dynamics are analysed, followed by the main motivations and ways how to partner with the 
identified key partner groups in the biotechnology industry. 
4.1 Case context 
In this section, I will present the empirical findings concerning the case context factors that 
affect the partnering strategy. To start with, the commercialization decisions made by the 
company that create the basis of the entry and partnering strategy choice are depicted in 
Figure 4.1. As a result of these decisions, the innovation had been set up as an internal start 
up aiming to commercialize the innovation in an unfamiliar industry. The product was 
offered as a material. 
 
Figure 4.1. Flowchart of commercialization decisions 
4.1.1 Characteristics of the home industry 
The home industry of the parent company is the material manufacturing industry. According 
to the findings, the core business logic of the parent company and the material industry are 
characterized by big investments, business-to-business activities based on large volumes and 
stable customer relationships, while readiness to invest or risk is relatively small and easy 
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wins are expected. In the 1990s large material companies took risks and bought out 
companies but nowadays have become more risk-avoiding in their investments, especially 
when they do not know the industry where they do business. Traditionally, these companies 
have wanted to execute activities in-house and control but this is changing towards 
partnerships and joint development agreements. For a listed company, the owners’ 
expectations also reinforce the aversion of risk. What comes to innovations, according to the 
case company, incremental innovations (instead of radical or disruptive) “are the DNA” of 
the company. 
Furthermore, according to the findings, networks and identities are strong inside the home 
industry, but there is little networking between different industries and the employees’ 
backgrounds are rather homogenous. The small amount of connections to other industries 
may make it a challenge to diversify to another industry. However, despite being a somewhat 
typical incumbent in its home industry, the parent company is perceived by some informants 
as more prone to try new innovations than some of its peers. As one informant describes, the 
traditional companies very rarely develop the new ideas themselves, which may be due to 
the new ideas being outside the competence of the parent company, and due to the resources 
of the parent being bound elsewhere. Despite this, the parent company has chosen to tackle 
the challenge.  
The home industry is an established industry where incumbents play in the home market or 
neighbouring markets, exploiting existing monopolistic advantages and prefer control 
ownership and in house activities. Investment are big but the risks are thoroughly calculated. 
Geography matters in the sense of choosing locations but the level of internationalization of 
the incumbents is high. This features also coincide in many ways with the five classic theory 
factors presented in 2.1.1.    
4.1.2 Complexity of the target industry 
In the target industry, on the other hand the case company needs to address both the general 
complexity of the market and the specific de alio newcomer challenges of lacking knowledge, 
access and networks. Furthermore, one case company interviewee felt that even inside the 
biotechnology industry, there are easier segments than the target segment. The informant felt 
that in a certain other segment, for example, even receiving information from customers was 
easier, and selling was more straightforward. In the target segment of this case, marketing 
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the product was more complex and for example required scientific research results backing 
the product. 
Moreover, an experienced industry analyst describes the industry as virtually integrated. On 
one hand, the deep science and inventions are the basis of product development. Innovations 
concerning the human physiology are fuelled by competition, little time, big risks, big 
upsides and venture capital. On the other hand, the big distributors and the Big 
Pharmaceuticals form the more typical marketing and sales function of the industry, taking 
the products to doctors and hospitals.  
Based on the analysis of the empirical data, the dynamics of the target market are 
summarized in the Figure 4.2: 
Figure 4.2. Biotechnology industry dynamics in the segment investigated in this research 
(Based on the analysis of data) 
The key factors of this complexity identified in the data are 1) Deep science, 2) Regulation, 
3) Big investments, high risk and uncertainty in business, 4) Symbiotic behaviour and 
partnering dynamics (developed to address the risk) and 5) Little time to learn due to 
acceleration phase of the market and competition based on learning races. 
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Firstly, the deep science complexity factor includes various dimensions. According to an 
experienced informant, the innovations and ideas are based on science and originate in the 
academic world. Furthermore, the complexity is exacerbated by the fact that biotechnology 
innovations work very closely with the human physiology and biology (as opposed to 
chemical and mechanical engineering innovations) (Interviewee A). In the case company 
activities, the deep science is present as none of the venture team is a biologist and they have 
identified a need for sophisticated laboratories (Interviewee F). Furthermore, this need of 
deeper scientific understanding is reflected in the experience that the venture lost a customer 
due to not being able to answer the deep scientific questions (Interviewee L). However, the 
parent company prefers not to dive deep into science (Interviewee C). 
Secondly, the regulatory aspect of the complexity is linked with the human physiology and 
safety, as a big part of the strict regulation of biotechnology applies to the diagnostic 
applications and the innovations interacting with the human body. A further requirement are 
the clean rooms and other laboratory equipment aspects. The case company considers it 
easier to operate in the academic setting due to not needing to get involved with these 
demanding regulatory processes (Interviewee H). However, an experienced biotechnology 
expert recognizes the regulation as a possibility to build competitive advantage and barriers 
to access against the competitors. This can be done by developing an application and taking 
it through the regulatory process, including reimbursements. After the regulatory approval 
has been obtained for the innovation, its contents remain “frozen” and other products cannot 
be introduced in place of the original ones. Furthermore, the approval may be exclusive in 
the sense that the customers are obliged to choose among the small group of approved 
procedures (Interviewee A). 
Thirdly, Furr et al. agree with Pisano by listing the target industry as one of the most high-
risk compared to other industries (Furr, Dyer & Christensen, 2014):  
In the R&D side of the industry, it’s venture capital, innovations and big risks. But 
also the big upsides. Interviewee A  
One key reason for the big investments and risks are the aforementioned needs to engage in 
deep science and regulation related activities.  
Fourthly and consequently, partnering has become an extremely important tool in the 
industry to address the specific features of the industry, especially the need for big 
investments, uncertainty and risk. Partnering in biotechnology industry has actually 
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developed towards such a distinctive, symbiotic direction as a survival strategy responding 
to the extremely (and for start-ups, often fatally) high risk (Pisano, 2006). 
For a de alio newcomer, partnering is even more crucial as the conventions of the complex, 
non-familiar industry are hard or impossible to learn in-house. Still, partnering is a necessity 
for all industry actors: 
if we think about the business model, every kind of partnering is essential [...] 
Partnering is extremely essential. Interviewee A 
Furthermore, due to the big investments and risks, partnering dynamics has developed 
towards a symbiotic direction where the ultimate goal of the newcomers is not to disrupt or 
overthrow the incumbents (that is, Big Pharma), but to reach a successful collaboration or 
exit arrangement with them (Furness, 2016; Bagchi-sen, 2007). The enormity of the 
investments and risks inherent in the biotechnology activities is too much for start-ups to 
bear, there is difficulty to obtain such funding, and these resources are often controlled by 
the enormous pharmaceutical companies and venture capitalist:   
The whole business model of discovery and product development companies is based 
on partnering. They partner with Big Pharma who takes the product to the market. 
And there are different partnership models and very often Big Pharma are for 
example in research collaboration. Interviewee A 
On the other hand, the companies of Big Pharma compete for the small companies: 
Big Pharma compete among each other and they all want to buy a particular 
company. There is huge competition at the moment. Interviewee A  
An important feature is also the tendency that different parts of one company may have 
different type of relations to other companies: 
it’s the distribution part [of the company] which is our competitor but at the same 
time, [another part of the company] is one of our largest suppliers. Interviewee B 
This adds further to the complexity of the biotechnology industry dynamics. All these 
complexity factors together may form substantial barriers for de alio entry into the industry. 
As partnering proof to be such a central factor, I also conducted a social network analysis of 
the industry networks where the partnering dynamics and value networks of the target 
industry were analysed. The results are crystallized in Figure 4.3, Figure 4.4 and Figure 4.5. 
In the figures, the participant’s names are anonymized by using numbers. These number 
inside the nodes refer to their order in the original data set and have no further bearing to the 
interpretation of the graphs. Also, the size of the node is proportional to the number of its 
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connections to other nodes (not size of the organization). The different types of relationships 
between network participants are shown in the legend. 
 
Figure 4.3. The figure shows a sample of the industry network  
From the graph, it can be seen that the participants of the value network are networked in a 
manner where everyone is well networked and has connections to various other participants. 
This does not depend on for example if the participant is a small or large organization. The 
core of the network is especially tightly knit, and formed by numerous well networked 
entities, as opposed to a network type where the core(s) would be formed by one large 
organization, surrounded by smaller “satellites” with much less connections. The 
organizations in the tightly knit network core include both companies and universities plus 
other public research institutes. 
Considering the mode or type of the relationships between the participants, it can be observed 
from the Figure 4.3 that scientific cooperation and joint development together account for 
more than half of the perceived relationships (53.5%). This signals that the motivation of the 
partnerships is learning. On the other hand, supplier and distributor relationships form almost 
a quarter (23%) of the perceived total, which signals that the motivation for these 
partnerships is access to market.  
In addition to creating the main graph, the networks connections of two of the key 
competitors of the case company were separated from the data set and analysed separately. 
The results can be seen in the Figure 4.4. 
 54 
 
Figure 4.4. The network analysis for a competitor.  
 
Figure 4.5. The network analysis for another competitor. 
The Figure 4.4 shows the competitor at the centre of the network. Similarly, the Figure 4.5 
shows another competitor at the centre of the network. The network of the competitor in 
Figure 4.4 comprises of 100% learning partnerships, while the network of the second 
competitor in Figure 4.5 comprises of 94.4% learning and 5.6% access type of partnerships. 
This signals that learning as a motivation for partnering is even more emphasized among the 
competitors of the case company than in the industry as a whole. The partnering motivations 
reflect the phase in which the industry or company finds itself. The percentages mentioned 
above signify that the learning motivation is common and shared in the industry, all the 
actors are learning continuously. 
Moreover, from outside the graphical representation of the network, it is important to take 
into account the dense physical location clusters or hotspots in the networks of the industry. 
One case company interviewee mentioned that the Big Pharma companies continuously 
observe the clusters for new ideas. The clusters identified in the interviews are located in the 
UK, the US, France and Sweden/Denmark. The national value network in the case context 
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also has its own clusters, but according to two non-company interviewees, the value network 
is in many ways incomplete due to a phase of severe lack of funding in the past. Still, in a 
global field, no national network is isolated but connected with the international networks. 
This has led to researchers being recruited abroad and the actors in the national value network 
necessitating international contacts for certain activities. In my interpretation, the national 
network is nevertheless a potential point for tapping into larger, international networks and 
the hotspots abroad, for example via researchers’ networks and expatriate researchers abroad. 
Fifth, from the industry complexities in general, the de alio case company operates conscious 
of the time dimension. On one hand, this refers to the emergence / co-evolutionary / co-
development phase of the target segment. According to an experienced industry expert at the 
moment there is lots of activity in the segment due to an influx of tiny new companies with 
problems to differentiate their product from the competing products. The interviewee 
considers that the period of influx is in its middle point, with approximately four years left 
of the active phase. After that, only some of the firms will survive. This corresponds to the 
industry life cycle theory tenets that the segment activity accelerates towards the rise of a 
dominant design and subsequent industry consolidation. 
On the other hand, the case company is conscious of the de alio specific time dimension: in 
order to compete successfully in the challenging situation, it needs to bridge the asset gap 
and leverage the lacking assets to a sufficient level with considerable speed, keeping in mind 
the time frame and the window of opportunity indicated by the market situation and industry 
life cycle stage. Considering the situation, some of the knowledge, contacts or access 
opportunities may not be possible to develop on one’s own, or this would take too much time 
compared to the available time frame. Partnering is identified in the case company as a way 
to gain these resources rapidly. The motivation dynamics and the corresponding possibilities 
for entry strategy are analysed in the sections 4.2 and 4.3 respectively. 
4.1.3 De alio dynamics 
In the previous subsections, I examined the home and target industries of the case company. 
In this subsection, I will analyse the de alio dynamics of the case company connected with 
operating in both of these two realities simultaneously, and balancing between them. In 
theoretical sense, this refers to ambidexterity, which was discussed in section 2.1.4.3. 
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First of all, the team in charge of the commercialization of the new product is structurally 
placed as an internal start up within one of the departments of the parent company (see Figure 
4.1). Altogether, the parent has various internal start-ups, which have a common CEO to 
steer them.  
 The parent company, unlike many other innovators in the biotechnology industry, does not 
wish to sell the product (exit) but develop it into a new business area. For the same reason, 
it does not wish to turn the venture into a spin-off, which would be very common in the 
biotechnology industry. In addition, most of the competitors of their product are university 
spin-offs. According to case company interviewees, an advantage of the internal start up 
structure is to be part of a “big, reliable company” (instead of a start-up) when negotiating 
with customers and potential partners. On the other hand, as an integral part of the listed 
parent company, it must adopt a communications and marketing policy that keeps a low 
profile and avoids creating excess hype. This is a disadvantage compared to its competitors 
who can choose a more “visible” marketing strategy: 
being careful in the sense of not doing these investments, because that is a public 
signal that we have moved to a direction. [...] Do they want to make this public at 
all, public in a big way. Because that affects directly the item that interests them, the 
share price. And then the expectations accumulate also based on that. Interviewee D 
Moreover, the internal start up is not to look for venture capital which is common for start-
ups in the biotechnology industry. Instead, the venture is to be financed by the parent 
company. This means that some internal selling is involved instead of pitching the idea to 
external financiers: 
if start up financiers are external, then for us it is this corporation, and because of it, 
part of the job is the corporate internal sales/validation, entering the strategies. 
Interviewee C 
While this is an advantage, it also implies consequently that it is not possible for the internal 
start-up to obtain knowledge, contacts or mentoring from an experienced biotechnology 
industry venture capitalist, as the financier is the de alio parent company.  
Another dimension of the de alio dynamics, is the vision for the new product developed in 
the internal start-up and the parent company. The product is to become a platform for more 
products, the start of a new business area, a possible diversification and transformation 
modelled after other traditional manufacturing companies that entered de alio, using for 
example acquisitions:  
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If we look at the German chemical giants who have been in the commodity chemicals 
[...] some of them have made a very fundamental transformation, for example Bayer 
into the Life Sciences, and more and more someone like BASF is going to Life 
Sciences and buying Life Science firms here and there. They are quite traditional 
companies, too. Interviewee C 
For the case company, the product as a platform means supplying material for different 
biotechnology applications. This one product alone in the current target segment is not big 
enough business for the parent company. Hence the company is planning to develop more 
application areas in-house and with partners in order to expand to more products and 
segments using the first product as the platform: 
I believe that in some point, if it goes according to our plans, [this product] will be 
left smaller than the ones coming afterwards. But this, it is the first one. 
Interviewee K 
However, dire need of the case company to learn the target industry in order to make the 
vision reality, is illustrated by the description of the target industry by a case company 
informant: 
There is Big Pharma and the academia and the firms and these are the main players. 
But, after that there is the whole ecosystem which for me has always been a sort of a 
cloud. An amoeba that lives out there in the world. Interviewee D  
As discussed in 4.1.2., in comparison to material industry, the target industry and segment is 
perceived by the case company as more complex and the marketing process more demanding. 
The segment in question is even considered more demanding than certain other segments of 
the biotechnology market. This perception of complexity may be reinforced due to the target 
segment not being familiar. However, as discussed in 4.1.2, it can be argued that the 
biotechnology industry and the target segment in itself have certain characteristics that 
render them more complex than certain other industries and segments, even for established 
participants. 
4.2 Why partnering? Motivations, targets, desired outcomes of 
partnering 
In the context described in the previous section, (a de alio market entry without target 
industry specific knowledge, networks or access), some of the necessary resources may not 
be possible or fast enough to develop them in-house, within the window of opportunity 
available. In order to examine the partnering options, for example, type of partner and mode 
of partnership, one must look into the motivations of partnering. In this section, I will present 
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the empirical findings concerning the motivations affecting the partnering situation. To begin 
with, one case company informant summarized the general reason for partnering as opposed 
to in-house activities. The informant’s view is aligned with the longitudinal trend discussed 
in chapter two, the rise of importance of partnering: 
Developing the new is nowadays based strongly in building the network, so that you 
try to cooperate in the value chain, and not work alone in the researcher’s chamber 
and then after a few years go to market and the product does not work or there is no 
business. Interviewee E 
The informant implicitly refers to the need to keep learning the customers’ needs.  
Summarizing, In the research material, two main motivations for partnering stand out: 
learning and access. Three further main motivations were also identified and the complete 
list is described in Table 4.1. 
Table 4.1. Summary of partnering motivations identified in the empirical data 
Partnering 
motivations 
Description 
Learning gaining knowledge assets on both biotechnology business and science 
Access overcome barriers of access to Big Pharma, KOLs, market in general, co-
development opportunities, infrastructure such as extremely 
sophisticated laboratories 
Competitive 
positioning 
firms and academia both operate in competitive dynamics where a 
newcomer and a new product represent an opportunity for obtaining a 
competitive edge against their peers or a possible danger if their peers 
should grab that opportunity first; industry life cycle: preparing for 
consolidation and shakeout (see life cycle theory) 
Time 
dimension 
accelerating the processes and acting within the window of opportunity 
Mitigating 
risks 
sharing risks of big investments, experimenting 
 
The findings on learning and other main specific motivations for partnering are discussed in 
detail in the following subsections.  
4.2.1 Learning from partnerships 
The findings on learning, that is, (developing intangible knowledge assets) suggest that for 
the informants, learning means both the deep biotechnology science as well as the 
biotechnology business conventions and needs of the customers, partners and the industry as 
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a whole. As the main partner types identified in the empirical data are the Big Pharmaceutical 
companies and the academia, the prioritized learning goals perceived by the informants are 
learning both the deep science as well as the business logic of these two key actors. It is also 
interesting to note that this very study and the research project with a business school 
constitute a part of a learning effort partnership with the motivation of understanding the 
business logic of the target industry. A case company informant summarized:  
No-one in the team is a [biologist]. And none has a background in the 
pharmaceutical industry. So it is a minor negative aspect, although we are experts 
with materials, yes. But we should have a little more specific knowledge, according 
to my opinion, on the market where we are going. This obviously is related to in 
which part of the value network are you, and of course we are learning enormously. 
[...] we also have contacts with pharma companies. But our partners are more 
leaning towards research, either university people or suppliers. It would of course 
be easier if, say, a former employee of Novartis worked in the team and would 
already know the markets and the ways of working. Interviewee F 
An experienced target industry expert agreed on the business learning aspect, stating that it 
is good to have fresh ideas but when a company is looking for partnerships and competitive 
advantage, it probably wishes to hire industry experts. This is because the company lacks the 
long term understanding of the target industry and its conventions, and that may make the 
partnership negotiations hard for it. 
4.2.2 Access 
The second most prevalent partnering motivation, the motivation of access to the market, is 
perceived by many informants first and foremost as access to business with the Big Pharma, 
which would unlock the sales potential:  
what comes to Big Pharma [...] more than anything we are looking to access their 
sales network and the existing networks with our product. To get it there in the 
distribution, that would give it visibility [...] It is absolutely clear that [the material] 
should be sold [in massive quantities] to the Big Pharma instead of [tiny quantities] 
to the Academia. Interviewee D 
However, access had not been achieved by simply directly contacting and pitching the Big 
Pharma, as one case company informant told, but more research on the science side of the 
product was necessary. Conducting that research in-house and with the present means had 
been too slow and another provider had been chosen by the Big Pharma.  
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Hence, although the case company informants do not consider academia a massive customer, 
several informants expressed that the academia is an indispensable key partner in order to 
access the business with the Big Pharma: 
the [researchers] may have contacts to Big Pharma and it opens the way. [...] the 
Academia is more of a route to the Big Pharma [...] there you do the basic research 
and uphold it. But the actual sales, they go via Big Pharma in the end [...]. 
Interviewee D 
Moreover, apart from overcoming barriers to entry to market and networks, one motivation 
for partnering was identified as accessing the use of very sophisticated scientific laboratories, 
which the new venture could not afford and the parent company was not excessively willing 
to finance. This also was seen as a motivation to partner with the Academia. However, the 
academia is not easy to access either, which will be further discussed in section 4.4.  
Concluding from these findings, the industry network is perceived to be on one hand a closed 
network with barriers to entry, where a newcomer needs to have reference of one participant 
to access others. However, at the same time, by entering the market one is already part of the 
network, although it is the continuation of the process which defines one’s position in it. 
4.2.3 Competition and positioning in the market 
In order to position the case company in the target market, the case company informants 
perceived it necessary to partner, as it was observed in the previous sections that pitching the 
customer directly had not yielded the desired results.  
The case company had not expressed an explicit, definite choice of business model or desired 
position in the network before or during this study, and the differentiation from other similar 
products was underway. In part, the knowledge produced by the research project was thought 
to help in this respect. Nevertheless, supplier position was mentioned as a preliminary 
preference, and this remained during the study. Irrespective of the position or business model 
choice, however, partners were identified to be in key role in building the desired position 
and competing against other similar products. An example of this competitive positioning 
through partnering identified by informants was the supplier to the Big Pharma position, 
requiring university partners to legitimate the product, or develop an application to raise the 
product above the competitors.  
On the other hand, I found that in the industry, a newcomer is immediately part of the 
network as they appear in the radar of the other participants. The newcomer is evaluated and 
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positioned in the competitive landscape by each of the actors in the network. An example of 
this in the findings is a big distributor, extremely interested in new products and newcomers, 
continuously scanning for new partners because:  
we need a little competitive edge in relation to the present dominant player in the 
market.  Interviewee J  
This is an example of partnering motivated by competition-related reasons. This positioning 
in the network can be seen also as linked to preparation for industry consolidation phases, 
where firms without a strong position exit the market. The distributors were going through 
a consolidation phase. The informants also expected one to follow in the case company target 
segment too, after the emergence phase. In the dynamics of the industry, both the firms and 
academia operate in competitive dynamics where a newcomer and a new product represent 
an opportunity for obtaining a competitive edge against their peers (see Figure 4.2), or a 
possible danger if their peers should grab that partnering opportunity first. Therefore, a win-
win alignment with a partner may be found as each of the partners can provide the other a 
competitive edge against the partner’s competitors. For example, the firms are looking for 
access to references for their products from the researchers and the researchers are looking 
for products that could help them rise above their peers by facilitating scientific 
breakthroughs and other significant results. Furthermore, when partnering for competitive 
positioning, it is important to bear in mind the biotechnology industry complexity factor that 
part of one organization may be in a rival relationship and another in a collaboration 
relationship with the respective parts of another organization, as one distributor informant 
reminded. 
4.2.4 Time dimension: accelerating the commercialization 
According to the findings, the case company informants are aware of that “the window of 
opportunity is not open forever” (Interviewee G) and that the company needs to learn the 
business environment faster: 
when you are developing the new, you should be able to understand and learn rather 
quickly. [...] what we should improve [...] is to learn to recognize faster the new 
business environment value chains and ways of working. [...] I am not saying we 
need to do it better but we should, through some process, be able to learn faster, to 
figure these things out faster. Interviewee E 
This observation is supported by another case company informant who reported that finding 
out the scientific answers to the questions of Big Pharma customers by in-house research 
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had been too slow and therefore a competitor was chosen to provide the product for Big 
Pharma. 
As reflected by these examples, the time dimension of partnership motivations is a cross-
cutting theme, as it concerns accelerating all the other commercialization activities and is 
present in each of them. This means for example speeding up the processes of learning, 
access and positioning the product in the market. 
Furthermore, another time-related motivation for partnering is recognized by a case company 
informant. The interviewee pondered that not only this particular target industry requires 
faster action and partnering, but that a more general shift of gears or megatrend is presently 
underway. The informant commented that “nowadays, developing the new is based very 
strongly on building the network” (Interviewee E). This is the general development also 
identified by Dunning (1995). This implies also that the expectations of other industry actors 
and the industry conventions and ways of working needed to be taken into account. If one 
wishes to act in this changing environment, one needs to adapt, which the case company is 
doing in this commercialization process. 
4.2.5 Mitigating excessive risks 
Partnering was also identified by the case company interviewees as a way of mitigating risks 
of mainly two kinds. Firstly, they refer to sharing risks of enormous investments. This had 
previously been done in the home industry for example by forming a joint venture (which 
otherwise was non-preferred): 
manufacturing firms have started a joint venture only for the reason that nowadays 
[the infrastructure] could cost two billion plus binding 500 million for ten years [...] 
before they generate any money. In that case, even for big companies, the bound 
capital becomes so enormous that it is maybe worthwhile to share and divide the risk. 
Interviewee C 
As noted in section 4.1., sharing the risk of enormous investments is exactly the reason for 
the development of the particular partnering dynamics of the biotechnology industry as well.  
Secondly, one case company informant presented a very different point of view concerning 
partnering with motivation to mitigate risks. The risk was identified in the company policy 
of concentrating on incremental improvement, and not partnering or experimenting in new 
ways. The informant noted that the company itself considered this policy as risk-avoidance, 
but commented that “big risks have been taken by not having done anything” (Interviewee 
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G). The informant added that in order to truly renew, one “must take a risk”. The informant 
was not sure if the company had “the capabilities”, “mental flexibility” and “genuine desire” 
to do it. In order to mitigate this risk of not renewing in time, the informant recommended 
that the case company experiment with truly new ways of partnering.  
4.3 Modes 
I have now mapped the target network dynamics in chapter 4.1 and the key motivations for 
partnering on the part of the case company in chapter 4.2 (first and foremost, learning and 
access). Now it is time to consider the perceived possibilities and constraints for partnerships 
in this context, of which the empirical findings will be presented in this section. The 
heterogeneous portfolio of relationships and varied modes recommended by Powell (1998) 
is taken as a starting point. For this reason, I will discuss several mode option. On the other 
hand, the case company considers Big Pharma as their ultimate partnering preference and a 
relationship with Big Pharma as the ultimate goal. This is typical and consistent with the 
target industry dynamics. Hence, partnering with Big Pharma is taken as a focal point of the 
analysis and deepen in the section 4.4.1. 
4.3.1 Reaching targets by using suitable, corresponding modes 
As noted in chapter 2, the overall selection of modes for market entry and partnering abound 
and over time, different modes have been analysed from different perspectives in the 
literature. Similarly, according to the informants, the simultaneous use of many different 
types of partnering is typical in the industry. Certain modes are considered to converge with 
certain contexts and partnering motivations or goals. Considering the analysis of the 
partnerships networks of the target industry in section 4.1, the most common motivation for 
partnering was identified as learning and obtaining competences, as 53.5% of perceived 
partnerships supported this goal. The modes indicating these were scientific cooperation, 
R&D, joint development and similar. On the other hand, access ranked second with 23% of 
the relationships, consisting of distribution and supplier partnerships. The matching of 
motivations with modes is illustrated in Table 4.2: 
Table 4.2. Most typical partnering motivations and their corresponding modes 
Learning motivation Scientific, R&D, joint development and similar modes 
Access motivation Supplier, distribution and similar modes 
Other Management contracts, funding, ownership, joint venture, etc. 
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As the learning and access motivations rank highest both in the industry and in the case 
company, these modes (scientific cooperation, R&D, joint development, supplier, 
distribution and similar) need to be kept in mind when considering the perceived options, 
preferences, pros and cons for partnering modes in the case context.  
The fulfilment of the motivation to learn from (and especially how to) partner is available to 
a de alio entrant in all target industry partnerships regardless of the mode chosen, as the 
environment is new. However, continuous generating of new knowledge and hence learning 
is indispensable for all companies operating in innovation-based industries such as 
biotechnology (Powell, 1998), including the companies who were born in the target industry 
and have an established position there. In this sense, the learning-related modes listed above 
apply. The case company also prefers scientific collaborations and co-development, yet it 
prefers not to dive deep into the science, nor share IPR. 
Similarly, the fulfilment of the motivation of access is also available for a de alio in all 
partnerships, especially in the form of accessing more contacts, networks and knowledge. 
However, for organizations born and established in the target industry, the preferred barrier-
overcoming and access-creating modes are distribution and supplier relationships. 
Interestingly, although the case company has a strong motivation to partner in order to 
circumvent the barriers to access to the market, it is not interested in partnering with 
distributors, the most typical access-related partnership arrangement in the industry 
according to the empirical social network analysis. The parent company expressed a strong 
preference that distribution should be organized strictly in-house from parent company, not 
even through company-owned subsidiaries. This preference is understandable from the point 
of view of not losing direct contact and learning opportunity with customers, however also 
reflects the idea that distribution is seen in somewhat negative light as a simple transaction 
or loss of control (classic view), not from the point of view of a learning or access opportunity 
(recent view).  
Other modes may also be utilized for example to overcome or create barriers involving for 
example regulation. However, regulation-related issues are referred to further research, as 
they were not chosen as a focal point of the study at this point of the commercialization 
process. The parent company has crafted its strategy for short and long term and thereby set 
conditions to the use of the new venture as a learning tool and probe. Consequently, the 
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perceived preferences of the case company in the interviews are summarized below in Table 
4.3. 
Table 4.3. Preferred and non-preferred partnership modes as perceived by the case 
company 
Non-preferred Preferred 
joint ventures Supplier (in/out) 
Minority shares/corporate venturing Licensing (in/out) 
Spinoff  
Exit Joint development etc. 
External capital with mentoring In-house / full ownership 
Distributor Acquisitions 
Sales via subsidiaries of the parent company Internal start-up 
Extroverted visibility Restricted marketing activities 
Deep scientific involvement Basic level scientific collaboration 
 
In the following subsections, the focal point will be in the case company preferred and non-
preferred modes. Of these modes, spinoff, exit, external capital with mentoring and internal 
start-up were discussed in subsection 4.1.3.1. 
4.3.2 Constraints and modes not preferred by the case company 
Starting from the general principles, according to a case company interviewee, the company 
policy is that partnering arrangements requiring shared equity are non-preferred and must 
offer exceptional benefits to be chosen as a strategy: 
I always start by thinking what can be done without cross-ownership [...] ownership 
must bring something that cannot be reached by any other means. Interviewee C 
One of such exceptional arguments is forming a joint venture in order to share the inherent 
risks involved in enormous investments of billions of euros for decades, as noted earlier. 
Furthermore, the company has adopted a general guideline that corporate/capital venturing 
needs exceptionally strong arguments to be chosen as a strategy:  
[the company] has, at least until this day, chosen the policy of practically not 
engaging in capital venturing activities. This guidance has come from the highest 
management, but never say never, of course we always discuss as necessary. 
Interviewee C 
In the interviews, I found various reasons why partial ownership is not preferred. The case 
company considers that the added value of owning for example 30% of another firm is very 
questionable (preferring licensing or acquisition). The company perceives the new 
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businesses as too high risk and little probability of success, binding enormous amounts of 
resources and requiring heavy governance efforts: 
even a small firm, [...] if they’re relevant developers for the company, we are 
immediately talking about millions [of euros] and then the millions are bound in that 
firm. You should have quite a lot of money to make such a “one success, nine failures 
rate” function [...]  
the governance [...] you need to have someone sitting in the board and often in this 
kind of firms, it is not enough to go twice a year to have coffee and steer them but 
they usually need continuous assistance. That takes a resource to take care of it. On 
top of it you have the additional perspectives of a listed company. If you have 
minority shares of firms, you need to take that into account in the reporting. [...] This 
model of governance is quite heavy. Interviewee C 
According to the case company, one more reason for this non-preference guideline on 
corporate venturing is an earlier negative experience of corporate/capital venturing from 
some 15 years earlier, from the time of the IT boom of the beginning of 2000s. In that time, 
the company was able to create interesting new businesses, but did not know how to develop 
them further into strong, scalable businesses. Hence, in the end, the new businesses and the 
whole corporate venturing unit were discontinued. They were considered too far from the 
core businesses because their target market, product, materials and production technologies 
were all new to the company core. This lead the company to prune new ideas differently, 
looking for those that “clearly and rationally” match the core (Interviewee C). As a result, 
today, it is unusual that their business would involve both a new product and a new market. 
Some informants had the opinion that the bad partnering experiences of the parent company 
in the past may not have been due to a certain organizational mode such as shared equity but 
the way the partnerships in general were designed and maintained: 
some of the partnerships have had problems because the roles of the partners are not 
clear. And, of course [the corporation] being big [...] according to my understanding, 
would pretty much like to dictate the conditions of the partnership. Interviewee G 
More than one informant in the case company considered that the style of crafting and 
maintaining partnerships of the parent company may need to be adapted in order to operate 
in the new environment: 
you need to build trust, you need also to give something [...]. It is I think for [the 
company] quite a new style. It’s not that easy in the beginning [...] very different 
from traditional, heavy industrial production. Interviewee I 
Another contended:  
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I would consider it positive to aim for partnerships of two equals. These could even 
include joint ventures. 
[Interviewer: Is it in the company DNA?] 
No. […] It should be. It should have been for some time, probably the last ten years 
[…] this activity needs to be learned from A to Z. But in some limited case where you 
would have for example a joint venture of one of the new business areas, from there 
you could start practising it again […] the chemical giants such as BASF or 
equivalent, whose turnover is many- if not tenfold compared to [the case company], 
practising in a context like that could be rather interesting. Interviewee G 
Hence, a policy that a certain partnering mode (or, a partner type) is inherently a bad or a 
good choice, is not genuinely context sensitive. Negative and positive outcomes of 
partnering should be understood as more multifaceted: for example, the organizational 
culture and context sensitive partnering capabilities need to be taken into account and 
developed continuously to address the changing business environments and positions where 
the company operates. Attention need to be directed to crafting a win-win situation and 
aligning the business models so that both partners benefit when one executes its business 
model well. 
Furthermore, another non-preference concerns the scientific aspect. The views of the 
informants on the needed depth of the scientific involvement either in scientific activities, or 
at least understanding, vary. The case company has adopted the line that actual laboratory 
activities are ruled out and belong purely to their researcher partners (e.g. academia, Contract 
Research Organizations - CROs), whose role in the partnership constellation is to conduct 
basic work creating user data, application notes, visibility and product legitimating scientific 
papers and references, plus provide contacts to Big Pharma. Similarly, the company wished 
to avoid engaging in activities requiring deep science or regulation such as developing more 
sophisticated applications. This guideline is congruent with the company preference for 
activities that are strictly related to the core business and non-preference for experiments. It 
also reflects risk avoidance and wishing for easy wins through executing the familiar home 
industry business model of a material provider. However, some informants were of the 
opinion that more was needed to know about the target market science, and in order to 
success, the venture would need to dive deeper into the target market activities. 
Moreover, the company expressed a non-preference for the use of a distributor to market and 
sell the product:  
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you have these distributors [...] marketing channels and such, but no one was really 
interested in that [...] But the university researchers, I do not know if it makes sense 
to send products from here to separate researchers, as one has the customs duties 
and all, sending from [the company's home country] is difficult. If we had a 
distributor in some other country, they could take care of the small clients. 
Interviewee F 
The international subsidiaries of the parent company are not preferred either to be used in 
the distribution in order not to lose the direct contact with the customer. According to the 
case company informants, this preference serves the learning purpose. However, it also 
reminds of the classic manufacturing tenets of preferring in-house activities, control and full 
ownership.  
All in all, it can be observed from the material that the case company is placing numerous 
non-preferences to partnering modes. Some informants consider that the non-preferences 
may need to be relaxed somewhat in order to succeed in the target market: 
In the end it seems that the negative experiences of the past have influenced the company 
policies strongly, possibly overriding the present context. The effect of this to the overall 
case will be further discussed in chapter 5. 
4.3.3 Possibilities and modes preferred by the case company 
According to the informants, as a general principle, the case company prefers in the first 
place full ownership and in-house activities, and in the second place contractual agreements. 
[…] in most cases we build in a focused manner on the ideas that we believe can 
directly, piece by piece, be built into business areas fitting the company. Interviewee 
C 
Continuing in the same vein, the case company also prefers in/out-licensing or acquisitions 
and argues for it based on the traditions of the material industry: 
You either take [the technology] entirely via acquisition or you simply take the 
license. Interviewee C 
According to the case company, some 15 years after the latest corporate venturing 
experiments, the preference for these modes with strong control is deeply embedded in the 
corporate culture and “DNA”: 
The company culture is quite strongly such that we want to steer, control and lead 
those issues and firms where we work. I would not completely rule out a minority 
ownership but it is not in the company DNA. Interviewee C 
These preferences match the classic manufacturing industry theories discussed in chapter 2.  
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Furthermore, one of the most preferred modes of the company is being a supplier and the 
company is also using suppliers to fulfil its needs. 
It would be ideal, for example, if we had a couple of very big customers to whom we 
could sell directly. Interviewee F 
Selling directly was perceived as preferable in order to maintain direct contact (and control) 
of the customers. This preference also matches the classic ideas of control and in-house 
activities.  
The supplier strategy is considered as one strategic option also by informants outside the 
case company, although not necessarily the most recommended one: 
If there is a big firm in the background, that way you can reach some sales and get 
to compete with the other material firms. It is a strategic question, what size of a 
market are you after? [...] Do you want to be one of the material providers or do you 
want to go deeper into the biotechnology. Interviewee A 
However, experienced industry experts considered this position vulnerable due to 
fluctuations of sales and this concern was also expressed by a company informant. 
Furthermore, in the sales to academia, the fluctuations may also be rapid due to cuts in public 
funding. Moreover, in basic materials, the customer can easily change supplier if there is no 
clear competitive advantage and differentiation:  
Over the last ten years I guess there’s probably dozens of options which have 
appeared. [...] All of those suppliers now have the same challenge, how do they make 
people understand or get a feeling for how one[product] is better than another. 
Interviewee H 
While the case company repeatedly expressed a preference for being supplier or a material 
provider at the same time a company informant observes other options: 
Although we say that we are a material provider, yes, but all that we do here makes 
me feel that we want to be much deeper in the value chain. Interviewee F  
Practically, in the target industry, this requires for example deeper involvement in the science 
and research sphere. 
On the other hand, the company also prefers joint development for various reasons. Joint 
development is perceived as more flexible, involving lighter forms of governance for a listed 
company, and less binding in terms of both monetary and human resources. This mode was 
perceived in the empirical social network analysis and non-case company interviews as one 
of the typical learning related modes in the target industry and hence suitable mode for the 
commercialization process as well.  
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4.4 Key partner groups - With whom to partner? 
I have now discussed the findings on partnering motivations and modes. In this section, I 
will then present the empirical findings concerning the identified key partner groups in the 
context. 
4.4.1 Big Pharma 
As I noted in chapter 4.1, biotechnology is a symbiotic industry where other actors prefer a 
symbiosis with the incumbents, that is Big Pharma, instead of seeking to disrupt and 
overthrow them (to the contrary of Christensen’s theory of 1997). In the interviews, the case 
company expressed that partnering with Big Pharma is the most important goal in partnering 
and customer relationships. The case company prefers to act as a supplier, and material 
provider, selling directly to Big Pharma. However, some informants advised against offering 
only a material as the position is vulnerable. The parent company targets of a “big enough 
business” also raised concern with the supplier model: 
You can never be sure if they are going to order lots or little of the material in the 
end. In order to reach big sales volumes, will it be necessary to have all big pharmas 
as customers? Interviewee D 
Another option preferred by the company would be to engage in a licensing arrangement or 
research collaboration with Big Pharma. The long term goal expressed was to create a 
platform with the first product as a basis for a range of products. 
Due to the symbiotic dynamics, accessing Big Pharma is not easy however. According to the 
social network analysis conducted in this study, Big Pharma may maintain hundreds of 
partnerships and according to interviews, competition for their attention is fierce. Hence, the 
Big Pharma is in a position to choose their partners. 
According to the interviews, Big Pharma continuously scans for new ideas in the academic 
networks of the leaders of their research departments, scientific conferences and contacts by 
smaller companies. The Big Pharma engages in scientific and product development 
collaboration, yet they prefer the small companies to legitimate the offering first and not to 
enter in the riskiest development phase themselves. The Big Pharma also continuously 
rearrange their structure and ownership by buying and selling departments and small 
companies who have demonstrated enough sales. However, in the case company situation, 
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selling the venture was considered a non-preference and hence, partnerships with Big 
Pharma are the target. As an experienced industry expert comments: 
[... Big pharmaceuticals] may be more enthusiastic to cooperate when an application 
has been developed with researchers and proven that it works very well for screening 
drugs. [...] one could aim for a discovery cooperation developing a new assay for 
certain cancer types in order to develop better drugs, but one has to be careful not 
to end up in a position where you go with only a material. There has to be some 
research from the university, and build the application idea, and go to the big pharma 
with that as a spearhead. Interviewee A 
Consequently, in order to reach Big Pharma, the company may need more partnering with 
researchers irrespective of chosen business model. However, according to interviews, the 
case company is not willing to dive deep into science not pharmaceutical regulation, 
preferring to be only a material provider. 
4.4.2 Researchers and academia  
As discussed earlier, deep science is one of the key complexity factors to be addressed in the 
biotechnology industry. In the industry dynamics, the researchers are a potential access route 
to other customer groups by producing scientific data and references on the product. In this 
realm, the Key Opinion Leaders (KOLs) are the most important potential partners. Another 
important question identified is whether the case company wishes to engage in deeper 
scientific activities for example in the form of developing an application together with the 
researchers. These questions will be explored in this subsection.  
The case company informants expressed their desire and need to collaborate with research 
partners. Some were of the view that it may not even be possible to stand out among the 
competitor products and draw the attention of Big Pharma without developing something 
unique such as an application. Furthermore, they believed that something more sophisticated 
should be developed, as offering only material would be a vulnerable position due to sales 
fluctuations. An experienced target industry analyst recommended precision medicine as a 
trend to follow for application development if one wishes to get a larger share of the market.  
However, the views of the informants on the needed depth of the scientific involvement 
either in scientific activities, or at least scientific understanding, vary. According to the 
informants, the original preference of the case company is to act as a material provider for 
Big Pharma and leave the more sophisticated activities for the Big Pharma. The role of 
academia in this model is to provide basic information and legitimate the product, to conduct 
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basic work creating user data, application notes, visibility and product legitimating scientific 
papers and references, plus provide contacts to Big Pharma. The case company has adopted 
the guideline that actual laboratory activities are ruled out and belong purely to their 
researcher partners (e.g. academia, CROs), Partnering with the academia was mentioned also 
as a way to obtain access to infrastructure such as sophisticated laboratories. This may signal 
some differences of viewpoints between the parent company and the new venture. 
Whichever collaboration level the company may choose, legitimation or application 
development, the interviews showed that the key partner group inside the academia are the 
Key Opinion Leaders.  However, one of the case company informants suspects that as in 
another biotechnology industry segment, the Key Opinion Leaders are probably the target of 
a “bombardment” of marketing material, and for this reason very selective with whom they 
partner, similarly as the Big Pharma companies.  
Furthermore, adding to the complexity and barriers to markets and network access, 
biotechnology expert informants add some specific observations. The researchers to 
collaborate with need to be international, not only from the national network, and it is crucial 
to work with the most senior or second-most-senior Key Opinion Leaders, not only young 
scientists (although they may be easier and less costly to reach). According to an informant, 
in order to draw the attention of Big Pharma, it would be recommendable to take the role of 
a moderator between Big Pharma and academia, but this requires extensive networks in the 
academia: 
The national data is not sufficient, one should always do these things internationally 
[…] you have to have lots of researchers in the background [...] top research units 
are of course interesting [...] the younger ones and those who are not yet in the high 
professor positions may be [...] post-doc [...] with them is easy but it takes a longer 
time [...] you simply need to work with the senior Key Opinion Leaders or second 
most senior ones. Interviewee A 
Apart from academia, big experienced CROs were mentioned as a recommended partner 
type in order to reach the Big Pharma. However, another informant held the opposite view 
claiming that CROs only do what Big Pharma asks of them. Hence, the link is in the direction 
that Big Pharma creates the access to CROs. Therefore, the issue is debatable and possibly 
both views are right in different contexts of CROs, which were not elaborated in the data. 
Regardless of the type and nature of the scientific cooperation, it is evident that it is one of 
the key elements in partnering in the biotechnology industry. It serves both top motivations 
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for partnering: learning and access to markets, which moreover are inextricably interwoven 
with each other as one is needed to obtain the other.  
4.4.3 Distributors 
Another partnering key question to be solved by the case company is the distribution issue. 
Distribution is a prominent partnering mode in the social network analysis. It is linked to the 
motivations of access to market and to Big Pharma. According to the case company, it wishes 
to keep distribution in-house, in the new venture. Distributors or even the international 
subsidiaries of the parent company are not preferred to be used in the distribution in order 
not to lose the direct contact with the customer. According to the case company, this 
preference serves the purpose of learning the customers’ needs.  
However, according to a case company informant, some customers are obliged to purchase 
from certain sales channels, usually the big distributors. Moreover, the distributor 
partnership need not be exclusive, but may help reach the customers who are obliged to 
purchase from big distributors, without losing the ability to sell directly as well. One big 
distributor describes the target industry dynamics as follows. On one hand, the small 
companies need the massive sales network of a distributor to get their product to the market. 
On the other hand, big companies with a known brand have the option: they either sell 
directly or opt for a multi-channel strategy to get their products to the customer. The big 
distributors may also provide one access route to the Big Pharma, since as one distributor 
puts it, “Big Pharma are actually our biggest customers” (Interviewee B).  
According to target industry informants, distribution partnership may also serve for 
enhanced learning and access. Learning can be enhanced in a distribution partnership by 
choosing a partner who engages the de alio entrant in a mentoring dialogue: 
Well, the goal. usually is, to make money, right, so that everybody makes money and 
everybody’s happy […] And it’s usually more collaborative atmosphere let’s say 
because you all want the same thing […] And also regularly reviewing these, with 
quarterly business reviews, you need to discuss about what’s going on in the market, 
how is the products, performing, which ones are not performing, where are you 
selling so this kind of, keeping finger on the pulse is very important, so that you can 
then direct or put more effort in, web enrichment or, more training of the people and. 
so that’s definitely the main activity. Interviewee B 
Furthermore, in the distribution business, the distributors are consolidating, which affects 
the customer behaviour as well. As mentioned in section 4.2.3, due to consolidation the 
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distributors are actively looking for new products and partners in order to gain competitive 
advantage. This underlines their motivation to partner for competition-related reasons 
(defensive / offensive) as discussed in Chapter 2. The consolidation opens up possibilities to 
partner on a win-win basis.  
4.5 Summary of the empirical data analysis 
In the fourth chapter, I have analysed the research context of a de alio firm wishing to enter 
from material industry to biotechnology industry as well as the main motivations of 
partnering that de alio context produces (learning and access) and analysed the identified 
possibilities and challenges of partnering.  
The empirical data show a case context where the company operates in two very different 
industries simultaneously. The case company needs depicted in Figure 4.6 (learning, access, 
market positioning, speeding-up and mitigating risks) are congruent with the case context 
complexity factors (high risk, deep science, symbiotic relationships with incumbents and 
fast-paced development). One may also say that the complexity factors give rise to these 
needs. Furthermore, as in the target industry in general, also in the de alio context specifically, 
partnering is identified as an important way to alleviate the industry complexity challenges. 
The most important identified motivations for partnering are listed in Figure 4.6. 
 
Figure 4.6. Partnering needs, motivations and targets identified in the empirical analysis 
The motivations of the case company are aligned both with the ones presented in the recent 
theories in chapter 2 and also with the target industry findings on motivations. However, the 
case company poses specific conditions and ways to act to fulfil these motivations, needs 
and targets. These conditions and ways to act are less aligned with the target industry 
findings or the respective theories. 
Moreover, the features of the internal start-up structure shape the reality of the partnering 
choices, not least in the form of parent company preferences on why, how and with whom 
to partner. The empirical data show that the parent company has preference for control, full 
ownership and arms-length contractual modes, and non-preference especially for shared 
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equity modes. These preferences are congruent with the theory and findings describing the 
material manufacturing home industry of the case company. They are not aligned with the 
findings on the target industry partnerships aiming at trust, common goals and mutual benefit. 
Close collaboration is expected even in contractual arrangements. Some informants 
explicitly recommended that the case company adapt to the new business logic, not only in 
the target industry but little by little to some extent in the core as well, for the sake of general 
renewal. 
In a nutshell, it can be said that the most prevalent idea for a partnering constellation 
perceived in the case company includes the case company becoming a material provider or 
supplier for the Big Pharma. In the first phase, the target is to reach a substantial market 
share and business volume. Later on, this “probe” business and first product is to be 
developed into a platform for more products based on this first product. To reach this goal 
of collaboration with Big Pharma, the case company has identified the need to engage in 
scientific collaboration with researchers (e.g. academia, CROs) who can help to create 
legitimation, visibility, and user data in the form of scientific papers and references, plus 
provide contacts to Big Pharma. The global distribution is to be handled by the internal start-
up in the home country of the parent company to maintain direct customer contact.  
Among the informants both inside and outside the case company, points of view vary on 
which vision and corresponding partnering constellation is the most suitable in the short and 
long term to reach the sales volume and market share goals. Some informants agree with the 
vision of aiming at a material provider role. Another segment of the informants expressed 
their concern whether the strategy of being a material provider is enough to draw the 
attention of Big Pharma, to prevail in the competition against other similar products, or 
whether it can fulfil the target of sales volume and business size even if otherwise successful.  
The conclusion from this concern also varies: some consider a multiple-product model better 
and sufficient, while others strongly recommend aiming at something more sophisticated 
and unique. This means for example developing an application with a scientific partner and 
using this to leverage the company and the material into the radar of the Big Pharma. These 
strategic choices also imply different levels of scientific understanding necessary in each 
strategy. The more sophisticated the aim of the strategy, the deeper the scientific 
understanding (and possibly regulation) required. In any strategy, however, regardless of the 
direct involvement or not in actual laboratory activities and similar, the company needs to 
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understand their customers’ needs and problems in order to solve them. In biotechnology 
industry, this indicates rather deep understanding of their customers’ scientific activities. 
Moreover, the case company wishes to handle the distribution itself by the new venture, but 
some informants recommended using a non-exclusive distribution arrangement for access 
and learning. 
Furthermore, the views on the mode of partnership vary. The case company has preferences 
and non-preferences on which modes it wishes to use. Irrespective of the mode, the 
informants expressed the utmost importance of how the process and relationship of 
partnering is managed to create and uphold a fruitful win-win situation and trust between the 
participants. The present views and preferences of the case company are inherited from the 
home industry business logic and experience; therefore, learning how to collaborate in new, 
target market ways may be one important goal while entering the target market. 
Furthermore, when entering a new industry, it is important to learn the organizational 
capabilities and partnering conventions of the target industry and adapt to them. The case 
company has defined its vision as entering the industry and after the first “probe” product, 
diversifying to other products, gaining a considerable market share and business volume. It 
has defined the Big Pharma and the academia (especially key opinion leaders) as their 
preferred partner types. Similarly, the desired partner candidates will have defined their 
preferences about partnering. An established player in the industry has certain assets to offer 
to a partner candidate, while a de alio newcomer with a large multinational corporation as 
its parent organization may offer other kinds of assets. Successful collaboration hence 
requires finding a point where these sets of preferences intersect and a win-win match 
between them can be created.  
As one bears in mind the various challenges entailed by a de alio entry to a new market and 
an unfamiliar, complex industry with a new product, and the necessity to attract partner 
candidates willing to collaborate with a de alio newcomer, placing numerous non-
preferences may prove a challenge while attempting to create a win-win situation with the 
potential partner candidates. This might also make it more difficult to reach the expressed 
business goals, namely obtaining a substantial market share and business volume for the 
product in the given time frame or window of opportunity, plus proceeding to expand the 
range of products based on the platform. 
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Furthermore, as the preferences and the criteria of the case company stem from the business 
logic of the parent and the home industry (material industry), they may be optimal for the 
home industry but not necessarily fully compatible with the business logic or partnering 
conventions of the target industry: 
Considerations of what the others are used to encompasses not only the modes and contracts 
of partnerships, but the whole culture and behaviours during the process of forging and 
maintaining a fruitful partnership. Therefore, choosing the right mode is not the only success 
factor: what happens in the negotiations and during the whole partnership function as a 
thermometer on the quality of the partnership: the target industry informants as well as recent 
theories on partnering centred industries underline the trust and mutual sense of benefit.  
Therefore, one of the learning goals for a de alio newcomer may be (with the help of an 
experienced target market expert) to expand their partnering palette by learning more ways 
of partnering. This means not only the organizational modes or contract conditions, but the 
process of creating and maintaining a mutual win-win match through behaviours and 
constellations prevalent in the target market and compatible with the target market 
conventions. 
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5. DISCUSSION 
In the empirical part of this study (Chapter 4), I analysed the partnering motivations and 
preferences of the case company. In this chapter, the discussion of the findings takes the 
form of assessment of the compatibility of the motivations and preferences with each other 
and with the findings of network analysis and interviews, as well as theories. The focus is 
then placed in partnering with Big Pharma. 
First, I will compare the case company partnering motivations with the partnering 
motivations in the other empirical data and the theories. Then I move on to compare the case 
company partnering motivations to the case company partnering mode preferences expressed 
in the interviews. After this, I compare the case company mode preferences to the modes 
typical to the biotechnology industry identified in the network analysis and the non-case 
company interviews of experienced target industry actors, to find if these are aligned. 
Similarly, I compare the preferences to the classic theories of entry modes and the more 
recent updates of those theories, biotechnology, industry life cycle and ambidexterity 
literature, to analyse the level of alignment. These comparisons are depicted in Figure 5.1. 
As a result, I made an assessment to what extent the preferred partnering mode selection or 
“toolbox” of the case company is aligned and adapted to the motivations and targets to be 
reached on one hand, and the target industry dynamics and conventions on the other hand. 
 
Figure 5.1. Systematical comparisons of findings and theory 
5.1 Motivations for partnering 
Altogether, the study identified two main categories of needs of the case company, learning 
and access, that is obtaining new knowledge assets and overcoming the barriers to access. 
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Three further motivational factors, competition (section 4.2.3), time and risk, were also 
identified. Case company interviewees considered partnering as an important, even 
obligatory tool to fulfil the needs, as a de alio entrant to the biotechnology industry could 
not learn everything nor position itself in the competition in-house, and the process was 
found to be frustratingly slow. Partnering was also found to be a familiar method to share 
and mitigate the high risks involved. Commercialization operation motivations that appeared 
in the empirical data and recent theories can be specified as follows in Figure 5.2. 
 
Figure 5.2. Mapping of partnering motivations in the empirical findings and theory  
I found that the case company motivations of partnering identified in the empirical part are 
aligned with and supported by the motivations identified in the recent literature by Greis et 
al. (1995), Dunning (1995), Powell (1998), Chesbrough & Schwartz (2007) and Pisano 
(2006), the empirical network analysis and non-case interviews. Furthermore, learning and 
access were also identified as the two most prominent motivations for partnering in the 
network analysis. However, some concepts are interpreted differently: for example, 
mitigating risks is identified as an important partnering motivation in both classic and recent 
theories, but in the classic theories full ownership is considered “safe” and partnering “risky” 
while in the recent theories the opposite is true. Furthermore, risk in biotechnology involves 
profound uncertainty, while for home industry incumbent, the risk means big but carefully 
calculated monetary investment risks. The results of the comparisons are summarized in 
Figure 5.3.  
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Figure 5.3. Partnering motivations: summary of the results of comparisons 
In the empirical part of the study, the main target or ultimate goal of the case company was 
identified as accessing partnerships or customer relationships with Big Pharma, which target 
is typical in the biotechnology industry and hence compatible with the dynamics of the 
industry. Therefore, the discussion on with whom to partner (Section 5.3) will place a focus 
on the motivations and ways of partnering related to that target. 
All in all, various interviewees of the study explicitly underlined that partnering is extremely 
important in the business. In the biotechnology industry in general, partnering has reached 
such an integral position in the dynamics of the industry that wishing to partner is considered 
obvious and not actually questioned. On the contrary, not partnering might require 
justifications. This is aligned with recent theories such as McCarthy et al (2007) and contrasts 
sharply with the traditional literature analysed by for example Dunning (1995) and Sharma 
& Erramilli (2004), where control through ownership was the primary option. In the 
biotechnology industry today, partnering seems to have become the primary option for many 
activities in the industry, and in-house mode comes second.  
The beginning of this development trend was described by Dunning (1995) as he updated 
his eclectic theory of entry modes. This case study hence supports (in the biotechnology 
industry context) the findings of Dunning (1995) about the rise of the importance of 
partnering and provides an update to how the trend is developing. The snapshot update 
offered in this research carries specific importance, since the biotechnology industry is one 
of the industries in the forefront of this trend according to Pisano (2006), Powell et al. (2005) 
and Onetti (2014). 
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5.2 Possible modes for partnering in the biotechnology industry 
The case company preferences found in the study, similarly to classic manufacturing theories, 
are based on maintaining control and ownership through in-house activities if possible. 
Contractual relationships come second, yet not considered as partnering but simple 
transactions. Sharing and equity-related partnering are mostly considered exceptional and 
non-preferred, a special case requiring strong justifications. Recent theories prefer the 
opposite: long-term trust based partnerships with shared equity or contracts, and full-
ownership is considered an exception. 
Therefore, the identified case company preferences for how to partner were found to be only 
partially aligned with the partnering motivations of the case company, the biotechnology 
industry conventions, and recommendations expressed in the interviews. Furthermore, the 
preferences are more congruent with traditional manufacturing industry theories of market 
entry than the recent innovation-centred and biotechnology industry related literature. This 
can be observed by examining the key principles of the classic theories reviewed in chapter 
2 which compares the case context with the tenets of the classic theories, which in this case 
would suggest low control modes such as licensing and exporting. This seems to be in line 
with the company who expressed their preference for exporting, licensing, and partnering 
options on a non-equity basis, without rendering the product development or production to 
a partner. The results of comparisons are summarized in Figure 5.4 and elaborated in the 
following. 
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Figure 5.4. Partnering motivations and modes: summary of the results of comparisons 
One of the reasons of the preference alignment with classic manufacturing ideals may be 
that according to the interviewees, the mode preferences of the case company stem from 
home (material) industry experiences, especially from a set of negative experiences 
approximately 15 years earlier, later formulated and reified in parent company “thumb rules” 
or policies. This finding is supported by Hennart and Slangen (2014) who report that 
repeating past choices is common: 
Various studies have already argued extensively that mode choices are likely to be 
replications of prior choices made by the firm itself and its peers, with many of these 
studies reporting supporting evidence (Hennart & Slangen 2014, 118) 
This phenomenon also constitutes a possible avenue for further research.  
The finding that the mode preferences are compatible with the classic theories and only 
partially compatible with the recent theories may signal challenges in the commercialization 
and market entry processes. The classic theories were designed for the traditional 
manufacturing industry market entries, and it would be preferable that while entering the 
biotechnology industry, the mode preferences be compatible with that and no longer with 
the classic theories. Furthermore, interpreting Dunning (1995), a tradeoff is inevitable 
between needing to let go some of the classic-style control in order to gain the benefits of 
partnering. In partnering centered dynamics, this loss of control is balanced with trust, 
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business model alignment and reciprocity. The mode preferences in detail can be seen in 
Table 5.1. 
Table 5.1. Summary of comparisons: mode preferences, theories and target market 
conventions 
Entry/Partnering 
modes 
Recent 
theory 
(eclectic 
update) 
Classic 
theory 
Network 
analysis 
Case 
company 
preferences 
Typicality in 
target industry 
Deep scientific 
involvement 
Horizontal Contractual Learning Non-preferred Typical, general 
Basic level scientific 
collaboration 
Horizontal Contractual Learning Preferred Typical, general 
Supplier (in/out) Vertical 
backward 
Contractual Access Preferred   
Joint development, 
etc 
Vertical 
backward / 
horizontal 
Contractual Learning Preferred Typical, 
universities, 
start-ups 
Restricted marketing 
activities 
Vertical 
forward 
Contractual Access Preferred   
Distributor Vertical 
forward 
Contractual Access Non-preferred Typical, startups 
Licensing (in/out)   Contractual Other Preferred Typical, Big 
Pharma and 
R&D companies 
In-house / full 
ownership 
  Full 
ownership 
Other Preferred Exceptional; 
Core advantages 
Acquisitions   Full 
ownership 
Other Preferred Typical, Big 
Pharma and 
R&D companies 
Sales via subsidiaries 
of the parent 
company 
  Full 
ownership 
Access Non-preferred Typical, famous 
MNCs 
Internal start-up   Full 
ownership 
  Preferred   
Joint ventures   Partial 
ownership 
Other Non-preferred Typical, big and 
small companies 
R&D 
Minority 
shares/corporate 
venturing 
  Partial 
ownership 
Other Non-preferred Typical, big and 
small companies 
R&D 
External capital with 
mentoring 
  Partial 
ownership 
Learning / 
Other 
Non-preferred Typical, start-
ups 
Spinoff   Partial 
ownership 
  Non-preferred Typical, 
universities 
Production Vertical 
backward 
  Other Non-preferred   
Extroverted visibility       Non-preferred Typical, general 
Exit       Non-preferred Typical, start-
ups 
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From the Table 5.1 it can be seen that the preferences are only partially aligned with the key 
partnering motivations of learning and access expressed in network analysis, as the 
preferences lean towards prioritizing full ownership, control and in-house activities, or 
contractual arms-length transactions, in for example marketing and sales, product 
development and production. Partnership potential is mostly seen in customer relationships, 
where the case company acts as material supplier to the other party. In the scientific research 
activities, the company does not wish to enter deeply, but prefers to only sell material and 
obtain the necessary references from customers, that is, via transactions. Developing 
applications is also considered as an activity of the customer, not the material provider. 
Considering distribution partnerships, the positive potential side of valuable learning or 
access opportunities had not been recognized or was overshadowed, as the activity was 
mainly seen from the point of view of losing control of the customer contact to the distributor.  
In general, the atmosphere reflected in the interviews seems to be that the company wishes 
to participate in the business of the biotechnology target segment, but does not wish to get 
deeply involved in the continuous sharing and presence in the relationships and networks. 
This contrasts somewhat with the success principles that experienced biotechnology industry 
actors expressed in their interviews: maintaining preferably long-lasting relationships in 
which the partners build synergies, common goals and trust. In the literature, this is expressed 
in terms such as aligning the partners’ business models for mutual benefit (Chesbrough & 
Schwartz, 2007).  
Therefore, the awareness of the motivations and needs regarding the target market is there, 
but the partnering mode selection and how to maintain partnerships “toolbox” of the case 
company is not yet fully aligned and adapted to the motivations and targets to be reached on 
one hand, and the target industry dynamics and conventions on the other hand. The expressed 
preferred mode selection includes many constraints, which leave the mode selection 
“toolbox” of the de alio entrant perhaps smaller and more limited than is needed to reach the 
ambitious targets of the diversification and commercialization process.  
Indeed, there are also cases when it is normally unwise for a company to partner (see the 
core competencies, Chesbrough & Schwartz, 2007), there are less popular modes also in the 
biotechnology industry, and not every partnership opportunity is worth seizing. However, 
limiting the selection of modes beforehand may limit the opportunities of creating a win-win 
match with partner candidates and hence jeopardize the value-creating and value-capturing 
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in the target market through fulfilment of the motivations of learning, accessing and 
competing in the target market in a timely and risk-mitigating manner. Moreover, although 
learning from experience is one important way of accumulating knowledge, the preferences 
expressed in this case were based on generalized home industry business logic and historical 
data, instead of the target market business logic and real time context-specific analysis. 
Therefore, practical learning and adaptation to the biotechnology partnering conventions and 
capabilities would be the recommendable next step.  
The empirical findings of a wide array of partnership modes classified as typical in the target 
industry are congruent with the argument of Powell (1998) that a heterogeneous portfolio of 
relationships is typical, even indispensable in the industry. Therefore, one of the ways to 
align the partnering mode selection would be to create the heterogeneous portfolio of 
relationships typical in the biotechnology industry, presented in the literature review. Some 
types of partnering dynamics are typical especially in the target market (that is, 
biotechnology industry) and perhaps not so prominent in other industries, such as the home 
market (that is, material industry) of the case company.  
One of these typical dynamics is the deeper and more multifaceted meaning of networks. An 
example of this is that although an IPR portfolio is certainly important, a portfolio of network 
ties (or a network profile) is equally important. Powell (1998, p. 233) emphasizes that it is 
crucial for companies both large and small to learn from collaborations and construct a 
heterogeneous portfolio of collaborators that provides access to both the emerging science 
and technology and the necessary organizational capabilities.  
Moreover, he argues that a firm’s portfolio of collaborations is a resource, an important part 
of a firm’s value and a signal to markets, as well as to other potential partners, of the quality 
of the firm’s activities and products, because in biotechnology, innovation happens in 
networks of learning, rather than individual firms (Powell 1998, p. 229, p. 231). Furthermore, 
Powell (1998, p. 230) reminds, it is no longer necessary to have exclusive, proprietary 
ownership of an asset in order to extract value from it. Hence, a limited partnering mode 
selection toolbox may hamper the creation of this key asset, the network portfolio, while on 
the other hand, taking steps to create a heterogeneous portfolio may offer valuable 
opportunities to adapt the present mode selection and partnering conventions to the 
biotechnology industry. 
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Nevertheless, what comes to the specific key contents of the heterogeneous portfolio in this 
de alio case context, the empirical findings suggest certain directions. To start with, the 
specific motivations and targets of partnering with each key group were identified in the 
interviews. The role of the Key Opinion Leaders, researchers and universities is to create 
visibility, references, application notes, articles and legitimation, possibly help create a 
unique application using the material. The role of an experienced, large distributor would be 
to create access, visibility and user feedback plus act as a mentor of the newcomer in the 
new industry. The Big Pharma is the ultimate target and goal of the activities, as it is 
considered that the business will not be big or profitable enough without the Big Pharma as 
customers. The role of the CROs in the empirical findings is somewhat debated: they are 
important, but some informants argue that CROs can only be accessed via Big Pharma (who 
give them instructions) while other informants maintain that CROs can help to access Big 
Pharma. Altogether, the key groups mentioned above can form a heterogeneous constellation 
of partnerships, recommended by Powell (1998) and needed in order to reach the expressed 
goals. This logic is depicted in Figure 5.5 which extends the one presented (Figure 2.8) in 
chapter 2.  
 
Figure 5.5. Relationship between the partnering targets and the partnering portfolio 
Following this, Table 5.2 presents a summary of the findings on matching these partner types 
with possible partnering modes. However, one must bear in mind that the case company has 
not yet decided upon a definite business model, and due to this reason, the partnering options 
also cover a wider range. 
Table 5.2. Matching key partner type with possible partnering modes 
Key partner type Possible partnering modes  
depending on the business model chosen 
Key Opinion Leaders in the 
target segments 
Scientific (basic/deep), supplier 
More Universities Scientific (basic/deep), supplier 
Develop an application jointly 
with researchers 
Scientific (deep), co-development 
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Distribution partnership with 
the eye on enhancing learning 
and multichannel strategy 
Sales and marketing via target market intermediary 
(non-exclusive, multi-channel) 
Big Pharma Research, co-development, supplier, licensor 
CROs Research, co-development, supplier, licensor 
5.3 Possible ways for partnering with Big Pharma 
In the empirical part of this study, the case company expressed that partnering with Big 
Pharma is their most important goal in partnering and customer relationships. The case 
company preference would be to act as a supplier, material provider for Big Pharma. Another 
option would be to engage in a licensing arrangement with them. The long term goal 
expressed was to create a platform with the first product as a basis for a range of products in 
the long run.  
According to the findings from the network analysis and non-case company interviews in 
the empirical part of this study, the supplier and licensor roles are possible to reach with Big 
Pharma. However, it requires substantial groundwork because due to the symbiotic 
partnering dynamics of the biotechnology industry (Pisano, 2006, p. 91), practically 
everybody has the same goal as the case company, to partner with the Big Pharma. 
Furthermore, according to the network analysis in this study, Big Pharma may maintain 
hundreds of partnerships. Both of these factors means tough competition and differentiation 
from the competitor crowd, which was discovered in this study to be numerous, while at the 
same time the differentiation of the case company product from its competitors is still in 
process. This is also reflected by the case company experiences of the direct meetings and 
pitching of the product with the Big Pharma, which ended up with the Big Pharma losing 
interest in the product and choosing a competing product, as the case company did not have 
all the answers ready to the questions posed. This signals the requirement of deep scientific 
understanding typical of biotechnology industry (Pisano, 2006). Therefore, before the 
desired partnerships with the Big Pharma can become reality, it seems likely that the case 
company needs to consciously build steps towards their goal. 
On the other hand, although experienced biotechnology industry professionals considered 
the material supplier and licensor roles possible to reach for a de alio company if they have 
the backing of the large parent company, they also expressed concerns that these roles might 
not be recommendable considering the long run, even recommending to avoid “going only 
with a material”. Some of the case company interviewees also expressed concerns of the 
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fluctuation of the sales of the product according to the Big Pharma customers’ whims. 
Furthermore, some pondered that possibly the material only might not be big enough 
business to fulfil the parent company market share or revenue targets unless practically all 
Big Pharma companies chose to use the product. 
However, another possible option for partnering with Big Pharma was also discovered in the 
empirical findings of this study. The most prominent was a research collaboration after 
developing an application for the product for example with the academia. This reflects both 
the need to draw the attention of the Big Pharma and differentiating from the competitors by 
having an application half-ready before pitching or negotiating for a partnership, and also 
the need to develop a less vulnerable position in the market by having more than only a 
material.  
Moreover, this recommendation is congruent with the findings of the empirical part of this 
study and biotechnology literature, that the Big Pharma relentlessly scan the networks for 
new ideas, but no longer wish to enter the risky development phase (Pisano, 2006, p.91, pp. 
105-106). Instead, they prefer to wait for the start-ups to develop the ideas further and see 
which one of the competing crowd prevails. In this sense, they have exactly the same 
preference as the case company who hopes for the Big Pharma to do the further development 
of the product and its applications. Hence it seems unlikely that the case company could start 
a relationship with the prevailing conditions as neither of the parties would be willing to 
develop the applications. The situation corresponds to a non-alignment of business models 
lacking the win-win element of a successful partnership (Chesbrough & Schwartz, 2007). 
As mentioned earlier, using any mode, the case company will need to build the steps towards 
the partnerships with Big Pharma. If not by developing an application, the differentiation 
from competitors would need to be done with the help of other type of legitimation superior 
to competitors. According to the empirical findings, this can be done for example through 
references and scientific papers from the academia, especially the Key Opinion Leaders 
(KOLs) in the segment. However, this strategy encounters practically the same challenge as 
the direct Big Pharma contacts: according to the interviewees, practically everybody wishes 
to partner with the KOLs, and for this reason, the KOLs are saturated with propositions and 
marketing material. As a result, the companies need to have legitimation already in place, 
that is, convince them that they want to use the product but also to compensate the valuable 
time of these “star scientists”. According to an experienced biotechnology professional, the 
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more affordable and less saturated young scientists, however, are not an option fast enough 
as the only strategy, hence one needs to work with at least the second-most-senior KOLs in 
order to succeed within the window of opportunity. Furthermore, national data and 
researchers only were described as insufficient; the KOLs involved should be international. 
While the legitimation and differentiation of the product from its competitors is in process, 
it is not easy to convince customers, hence the references are key. As at the same time the 
case company places constraints to the partnerships, this may cause challenges to obtain 
references as well. 
As a conclusion, it seems that accessing the partnerships with Big Pharma may require efforts, 
investments and involvement beyond the size, breadth and depth for which the case company 
expressed preference in the interviews. Ironically, it seems that the preferred strategy of 
selling material directly to Big Pharma and not getting very deeply involved in the industry, 
its networks and the science (following the home industry business logic), seems unlikely to 
succeed in the biotechnology industry, because getting involved in the networks, the industry 
and the science seem to be a prerequisite for (and not a result from) reaching the most coveted 
partnerships as well as the substantial market share or revenue targets.  
As a result, the discussion returns to the issue of how in biotechnology industry, a firm’s 
portfolio of collaborations is a resource, an important part of a firm’s value and a signal to 
markets, as well as to other potential partners, of the quality of the firm’s activities and 
products. This is because in biotechnology, innovation happens in networks of learning, 
rather than individual firms, and it is no longer necessary to have exclusive, proprietary 
ownership of an asset in order to extract value from it (Powell, 1998, pp. 229-231). In order 
to fulfil the ultimate goal and target of partnering with Big Pharma, creating and capturing 
value and market share before the window of opportunity closes and shakeout of firms begins, 
the prerequisite may be to create a heterogeneous portfolio of relationships as resource and 
a signal to the Big Pharma, KOLs and other actors in the industry.   
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6. CONCLUSIONS 
In this chapter, I begin by summarizing the case study and presenting the answers to my 
research questions. Then, I continue by stating the theoretical contributions this study brings 
to the field of partnering and entry mode theory. Moreover, I draw managerial implications 
based on the empirical and theoretical aspects of the research and finally I suggest avenues 
for future research. 
6.1 Summary 
It is important to study firms finding and creating new markets, diversifying and entering 
them; especially when experiencing pressure in their traditional, mature markets and during 
the present turbulent times in the global economy. The new knowledge and contribution to 
the theoretical field offered by this study is created by combining classic and recent theories 
of partnering and market entry in a theoretical framework designed to study partnering in de 
alio context, and applying it to analyse a challenging case. The strategy context of 
introducing a new product into an emergent market in an unfamiliar industry is extremely 
demanding, original and interesting. The target industry itself is ranked one of the most high-
risk and complex, involving deep science, regulation, symbiotic partnering and learning race 
competition dynamics. On top of it, the case company faces the extra challenges of de alio 
diversification, ambidexterity and the entry timing into an emergent market stage, with the 
competition accelerating towards consolidation. All these factors contrast with the case 
company home industry which is more calculated and mature, and where the company 
enjoys the position of an incumbent. Even the competitive advantages the company has in 
the home industry are not guaranteed to apply in the target industry without adaptation. For 
all the above mentioned, a target industry partner is important and the partnering issues of 
de alio companies merit attention. 
Furthermore, the research is inspired by the observation that neither classic nor recent 
literature on market entry modes quite covers the entry of traditional manufacturing MNCs 
with a new innovative product to unfamiliar, emergent markets with completely different 
business logics. As Dunning argued in his update of the eclectic theory in 1995, globalization 
is changing the traditional manufacturing industries towards the rise of importance of 
partnering. The literature is keeping up with the change by covering the changing factors one 
by one. However, an overall picture has not formed yet (as a contrast to the classic, 
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overarching paradigms), which is indicated by the need to combine various recent theories 
in order to research a case that combines various new factors.  
In order to fulfil the academic objective of this study, I have combined, complemented and 
extended existing partnering and market entry theories to the extent possible in a Master’s 
Thesis, to provide new insights into their applicability in analysing de alio market entries in 
complex global industry contexts. The aim has been to comment especially on the topics 
where contribution is solicited in the academic community, such as the role of ecosystems, 
and networks in entry processes, a processual view of partnering and market entry, entry 
learning, the link between a firm’s resource-capability mix and entry timing, and innovation-
entry relations (Zachary et al., 2015, p. 1389, p. 1393; Journal of Management Studies 2016). 
The main research problem of the present study focused on how companies can manage the 
challenges of de alio market entry by forging partnerships. With whom, why and how to 
partner in the case context? 
I investigated the research problem by asking who are the key partners and why de alio needs 
to partner in this context. More specifically, what are the motivations and targets for 
partnering? Furthermore, I asked which are the possible ways or modes how to partner in the 
biotechnological industry and especially with the Big Pharma. 
The ultimate key partner group and target of the case company was identified as accessing 
partnerships or customer relationships with Big Pharma (for example research collaboration 
/ supplier depending on the business model), which is a typical target in the biotechnology 
industry and hence compatible with the dynamics of the industry.  In order to reach the target 
and more generally, to obtain competitive advantage, create and capture value in the 
biotechnology industry, a heterogeneous portfolio of supporting partnerships is necessary. 
Key partner groups for the portfolio are universities, Key Opinion Leaders (KOL) in the 
target segments, a distribution partner with the eye on enhancing learning and multichannel 
strategy and Contract Research Organizations (CROs). However, one must bear in mind that 
the case company has not yet decided upon a definite business model, and due to this reason, 
the partnering options also cover a wider range. 
Furthermore, the five most prominent commercialization operation motivations that 
appeared in the empirical data and the recent theories analysed in this study are to overcome 
barriers, secure assets, respond to competition, speed up processes and mitigate risks. The 
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de alio context and emerging target market further intensify the need to learn and access 
rapidly. Some of the necessary assets are not available without the help of a partner, or 
obtaining them alone would be too slow. Moreover, in biotechnology, partnering has reached 
such an integral position that wishing to partner is considered obvious and not partnering 
might require justifications. 
Then, investigating which are the possible ways how to partner, the study showed that 
various aspects must be considered. First, the partnering mode preferences of the case 
company leaned towards ownership and control, plus market transaction type contracts, non-
preferring shared equity. The expressed preferred mode selection includes many constraints, 
which leave the mode selection “toolbox” of the de alio entrant perhaps smaller and more 
limited than is needed to reach the ambitious targets of the diversification and 
commercialization process in time for the industry shakeout phase. This signals that further 
fine-tuning and adaptation to the biotechnology industry conventions may be necessary. 
However, the transition from this traditional partnering mindset to the target industry one 
requires a complete change of perspective, because the target industry actors’ preference is 
the opposite. It is based on long term-partnerships, aligning business models and win-win-
collaborating as default, while ownership is reserved to core advantages. It means losing 
some of the control and compensating this by building trust, as a prerequisite to gain the 
partnering benefits. Furthermore, operating in the target industry requires maintaining a 
varied portfolio of relationships as a resource and a signal to others. All in all, the target 
industry stresses the processual view of crafting and maintaining partnerships instead of 
mode choice as a one-time event.  
Furthermore, the results suggest that there are two main ways how to partner to position the 
product in the market. One is adopting a material supplier role and entering the science and 
business networks plus regulation only in limited depth and breadth. This mode and position 
was preferred by the case company and was also deemed possible in other findings. However, 
it was considered a fragile position even by case company informants and an experienced 
biotechnology industry informant recommended against it. For executing this model, the 
partnering mode selection may require adjustment for example concerning distribution. The 
other main position requires deeper and broader involvement in science, partnering networks 
and developing applications. This approach was recommended for a stronger market position, 
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more added value and market share, with “big enough” business volume compared to case 
company targets.  
Finally, the Figure 6.1 summarizes my contributions in the form of a partnering dynamics 
framework for a de alio company in the biotechnology industry. 
 
Figure 6.1. Partnering dynamics framework for a de alio in the biotechnology industry 
6.2 Theoretical contribution  
The theoretical contribution offered by this study is manifold. First of all, this study 
contributes to the literature development which follows the shift in global industries from 
traditional manufacturing towards innovation- and partnering-centeredness. The study 
supports the findings of Dunning (1995) on the rise of the importance of partnering. The 
study found that in biotechnology, partnering has reached such an integral position that 
wishing to partner is considered obvious and not partnering exceptional. This is also aligned 
with the recent partnering and market entry theories and contrasts sharply with the traditional 
literature, where in-house activity, control and ownership were the primary option. This 
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study provides a snapshot update to how the trend is developing. The update carries specific 
importance, since the biotechnology industry is one of the industries in the helm of this trend.  
As my comment to the debated saturation of the literature, I wish to point out that the reality 
that the literature investigates will not stop from changing and hence the literature will never 
become “ready” but needs to renew as well. At the moment the field is rather active and new 
knowledge is solicited explicitly (Zachary et al., 2015, p. 1389, p. 1393; Journal of 
Management Studies, 2016; Hennart & Slangen, 2014). With this study, I have contributed 
to some of the solicited themes and some of them I refer to suggestions for further research 
(section 6.4).  
Moreover, the findings of this study support Powell’s (1998) theory that in the biotechnology 
industry, a few key partnerships are not usually enough, but a whole portfolio of relationships 
is necessary. This study also contributes to the theory by exploring the possible de alio 
specific contents of the partnership portfolio in biotechnology industry and how it is linked 
with the motivations for partnering, the business model options and creating a win-win or 
business model alignment with a partner.  
Furthermore, this study supports the conclusion of Pisano (2016) that it is important that the 
various partnerships provide the company with learning on both the biotechnology science 
and the organizational capabilities and business conventions.  
Moreover, this study supports the theory of Powell (1998) underlining the importance of the 
processual view of partnering and the various aspects of learning such as learning from 
collaborations, learning how to partner and maintain relationships in the target market 
context. 
Furthermore, this study supports the theory of Dunning (1995), Chesbrough & Schwartz 
(2007) that it is key to maintain preferably long-lasting relationships in which the partners 
align their business models for mutual benefit, build synergies, common goals and trust; also 
in contractual arrangements such as distribution (which in the classic views were considered 
mere market transactions).  
However, I also find the classic manufacturing market entry theories and this study mutually 
supportive in some respects. Despite the changes in the global economy business dynamics 
in many ways (such as transition from nation-state centeredness to a global, multi-level 
perspective on locations), the classic theories’ market entry preferences of control, 
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ownership and in-house activities still apply in the home industry of the case company, that 
is a mature, traditional manufacturing industry.  
In addition, according to the case company interviewees, the mode preferences of the case 
company stem from home (material) industry past experiences, especially from a set of 
negative experiences approximately 15 years earlier, later formulated and reified in parent 
company “thumb rules” or policies. This finding is supported by Hennart and Slangen (2014) 
who report that repeating past mode choices is common and well documented in the literature. 
Repeating past modes may cause biased choices and therefore, whichever mode is chosen, 
it is advisable to choose modes in a context- and partner-specific manner, as the home 
industry best practices may not be directly applicable in an industry with different dynamics.  
Due to the challenges posed by different dynamics, the study supports Ansoff’s (1957) 
theory which names diversification to an unfamiliar market with a new product as an 
extremely demanding strategy of market expansion. The findings of this study point out 
several internal and external challenges that a de alio entrant needs to tackle successfully in 
order to prevail in the target industry, while at the same time operating in the home industry 
as well (ambidextrous). 
Further contextual challenges are posed by the entry timing. In the entry timing and industry 
life cycle literature, it is debated who has advantage in the emergent stage. The study 
indirectly supports the review findings of Peltoniemi (2014) who concludes that de alio 
incumbents find it very challenging to enter another industry where the market is in an 
emerging stage, due to less agility compared with start-ups. However, this study does not 
fully support the findings of Peltoniemi in the respect that de alio incumbents avoid entering 
in the emergent stage but tend to enter later, in the growth phase. The case company did look 
for other options before embarking on this venture, however, eventually the challenges of 
the emergent market phase did not deter it. This study supports these observations by 
pinpointing the challenges (and possible solutions) posed by this kind of a market entry in 
the case context, namely the time pressure caused by the window of opportunity before 
consolidation, difficulty of positioning in a market that has not yet taken form, competing 
against start-ups that are not affected by the restrictions posed by a parent company (yet do 
not enjoy the benefits either) and ambidexterity with two markets in different stages. 
The findings of this study also support the disruptive innovation theory by Christensen (1997) 
as I find that the incumbent case company in a mature industry has a strong incremental 
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innovation tradition and transitioning to another mode of action proved to be quite 
challenging internally (“the innovator’s dilemma”). The case company did embark on a 
transitional journey to another “s-curve” in order to create growth, as Christensen & Raynor 
(2003) recommends (“the innovator’s solution”). However, the case novelty and 
incongruence with Christensen is that the case company is not executing the disruption or 
new s-curve in its home industry, but in a completely different one. This strategy does not in 
itself protect the mature home market business from disruption (which is Christensen’s aim). 
Instead, the strategy aims to tackle the home industry structural change by expansion. 
Furthermore, the findings of this study on the case target industry do not support 
Christensen’s assumption that the aim of the companies in an industry is to disrupt the 
incumbents. Instead, this study supports the findings of authors such as Pisano who claim 
that in biotechnology industry, the companies do not aim to disrupt incumbents or turn into 
one, but form a symbiosis with the incumbents.  
Also, this study contributes to the literature by offering a view to the internal and external 
challenges and possible solutions for the companies who are in the ambidextrous, 
diversifying renewal process from mature, traditional manufacturing markets into new, 
innovation and partnering centred ones. The study shows that the process is not easy and 
merits further research, as the theories have tended to concentrate on only one market or the 
other, and the ambidexterity literature has concentrated mostly on ambidexterity concerning 
the same industry or neighbouring ones - not diversification with triple novelty. Due to these 
reasons, in order to analyse the case, I needed to combine various theories (life cycle theory, 
ambidexterity model and diversification theory) in a novel manner which is presented in the 
Section 2.1.4. 
This study supports the ambidexterity model theory in the sense that while acting 
simultaneously in two industries, the case company experiences the internal friction between 
the parent company core and the new venture, whose target market dynamics and industry 
life cycle phases are completely different. As recommended by the ambidexterity model 
structural separation, the new venture operates as an independent team. However, it is still 
placed within one of the core departments. During the research project, the team was 
relocated from the parent company global headquarters to what might be called a “mini-
cluster”, where it resides close to other target industry actors and the academia. The new 
venture is also steered by a senior executive team as suggested by the ambidexterity model. 
The senior team receives their information through the common CEO of various internal 
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start-ups and therefore, various levels of information filters, internal education and selling 
are involved.  
However, despite these structures and dynamics that are congruent with the ambidexterity 
model, pressure of the core towards the new venture is palpable. It is not possible to conclude 
from the data, from which sources or level exactly this pressure and the perceived traditional 
preferences originate. This would however make interesting further research. Also, there is 
a paradox in the sense that the structures of the new venture are somewhat separated from 
the core (assumedly to protect it from the pressure of the core, as ambidexterity model 
suggests), yet the parent company expresses explicitly that it does not foster ventures unless 
they are going to fit clearly and rationally as integral parts of the parent company business. 
Furthermore, the parent company traditional guidelines on partnering are strongly present in 
the steering of the new venture. From the case data it is not possible to pinpoint how exact 
is the match between the internal start-up structure of the case context and the ambidexterity 
model structure. Despite this, the conclusion from this study contributes to the ambidexterity 
theory: it signals that no amount of structural and physical separation from the parent 
company core can provide the new venture with possibility to operate with different 
dynamics, if the parent core traditional ideas are operationalized through the internal start-
up funding requirements.  
The data does show, however, that the venture informants are somewhat more target industry 
minded than the parent company ones. This shows that the venture does function as a 
learning probe but the learning and new information flows do not penetrate the case company 
layers immediately, automatically or uniformly. This supports the tenets of Powell (1998) 
that the company capabilities of absorbing new knowledge are extremely important and need 
to be fostered consciously. 
All in all, studying this intriguing case with an extremely demanding context has contributed 
to previous understanding in many ways. Furthermore, it has shown the challenges of 
renewal in practice. However, it has also indicated possible paths to follow to address these 
challenges of de alio market entry and partnering. I will summarize these practical 
contributions in the following section.  
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6.3 Managerial implications 
Drawing from the empirical and theoretical aspects of this study, I have made the following 
key observations concerning the managerial aspect of partnering decisions were made. 
1. Building a partnership portfolio as both signal and resource 
A firm’s portfolio of collaborations is both a resource and a signal to markets and potential 
partners, of the quality of the firm’s activities and products in the manner of a professional 
profile or CV. In the biotechnology industry it is equally important and valuable as an IPR 
portfolio. Choosing entry modes and partners, promoting heterogeneity and interdependence 
is key. Utilizing an extensive “toolbox” of entry modes, a company can choose the most 
appropriate one for each context, partner and need. It is an asset to aim for a portfolio that 
provides access to both the emerging science and technology and the necessary 
organizational capabilities. Key partner group ideas for the portfolio are Key Opinion 
Leaders (KOL) in the target segments, more universities, developing an application jointly 
with researchers, distribution partner with the eye on enhancing learning and multichannel 
strategy, Big Pharma (for example research collaboration / supplier depending on the 
business model), Contract Research Organizations (CROs). 
2. Being visible in hotspots and clusters 
Being visible in hotspots and clusters that have strong assets supporting innovation and 
opportunities for networking creates synergies. It may be possible to work also via 
researchers’ networks nationally and internationally: Are the expatriate Finnish 
researchers/Big Pharma employees one potential contact base in the hotspots? 
3. Assuming a network moderator role 
It is more recommendable to assume a network moderator role instead of seeking to 
monopolize the returns from innovating activities and forming exclusive partnerships with 
only a narrow set of organizations. According to research, successful firms position 
themselves as the hubs at the centre of overlapping networks. Learning, visibility and 
network access value may be obtained from leveraging the national network and clusters 
with the case company as (one of) the coordinator(s), because national biotechnology 
networks are integral parts of the international networks. In order to access Big Pharma 
collaborations, the company may wish to develop a link between Big Pharma and academia 
and act as a moderator in between. 
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4. Utilizing parent company size and experience to attract partners 
Taking advantage of large company backing is an asset that many start-up competitors do 
not have. This includes accumulated knowledge, managerial and organizational experience, 
resources and capabilities; the ability to learn after entry; large company stability image and 
resilience, common governance and multinationality. It is important to convince partners 
that the company is in the business for long term, in order to balance their possible doubts 
on a new entrant with less experience. 
5. Adapting a company’s partnering capabilities to biotechnology industry 
Competition in biotechnology is a learning race. Competition takes place simultaneously on 
parallel tracks: one involves learning from collaborations, the other concerns learning how 
to collaborate. It is key to develop an excellent ability to absorb knowledge, and disseminate 
and utilize it inside the organization so that the company has both access to knowledge and 
capability to utilize it and build on it. Learning and adapting to the conventions of 
biotechnology partnerships is important, especially fine-tuning the company ability to 
develop relational skills and mechanisms through which information flows. 
6. Engaging in co-development partnerships 
Co-development can significantly reduce R&D expense, expand innovation output, open up 
new markets that may otherwise have been inaccessible and discover new value creation 
opportunities previously unidentified. Most importantly, aligning business models with the 
partner increases the chances that the partnership can be sustained and perhaps expanded. 
The subsequent projects are faster, and more profitable. To sustain co-development 
partnerships, they need to be designed and implemented carefully. It is important to define 
the business objectives and articulate the business model. Also, study and understand the 
partner’s and others’ business models in the industry. Moreover, it is necessary to assess the 
capabilities you and the partner candidates have and need. Then, classify the capabilities as 
core, critical and contextual according to their role in the business model and negotiate 
partnerships accordingly. Concentrate on the “critical” capabilities that bring the most added 
value through partnerships. Next, determine the degree of business model alignment with 
partner and create win-win. Finally, in managing the partnership, it is important to think of 
future collaborations – not just the current need. 
 100 
7. Managing partnerships actively 
Finding mentors can help the company to maintain the partnerships and guide the company 
while adapting the partnering capabilities hands-on, by actually partnering. Most firms also 
have key individuals who function as network managers,” marriage counsellors” and honest 
brokers, providing the glue that sustains relationships between parties who have ample 
opportunities to question one another's intentions or efforts. According to the literature, the 
focus of partnerships should not be too closely on the transactional details; but in adapting 
the company's abilities to do relational contracting and building synergy-based relationships 
in the biotechnology industry way. As Pisano (2006) argues, “whether value will ultimately 
be created depends on the execution of the [partnering] project”. 
6.4 Suggestions for further research 
The study gave rise to various potential avenues for further research, which I will comment 
upon in this section. These are learning in de alio context, ambidexterity in de alio context, 
location issues (such as distribution strategy, regulation, clusters and hotspots), creating win-
win, aligning business models and maintaining partnerships, and entry timing (for example 
de alio in the shakeout phase and the supposed following growth phase). 
Firstly, learning in de alio market entry was a central theme in this study, and contribution 
to the entry learning theme is explicitly solicited in the academic community. Potential 
questions concerning the theme are for example: How do the de alio learning processes in 
partnerships take place in practice (may not be possible for researcher outside the company 
due to confidentiality)? What are the special de alio challenges of learning in a partnership 
and how can they be alleviated? How can de alio learning be promoted and accelerated? 
Secondly, ambidexterity was a key contextual factor, the relationship between the parent and 
the venture affecting every key aspect of the commercialization process. Potential questions 
are for example: The parent wants the venture to become an integral part of the business in 
the future - how do the two different industries coexist in the core of the same company? 
How does this aspiration correspond to the ambidexterity theories? How much and in which 
ways does the home industry business logic affect the new venture despite the internal start-
up structural separation solution? Through what kind of practices can the adaptation to the 
conventions of another industry be done when the new venture is considered a learning probe 
for the parent company in de alio context? What effects does the structure have on the 
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learning and knowledge sharing dynamics inside the MNC? What does the internal start-up 
with a completely different industry innovation mean to the identity and internal dynamics 
of the MNC? 
Thirdly, location issues were touched upon in the study yet further contributing to the 
understanding of the multi-layered reality of global industries would be interesting. Potential 
questions are: How can the de alio solve the distribution question involving reaching the 
customers and tackling the varying regional regulations and challenges and other practical 
issues while maintaining contact with the customer?  Pros and cons of direct sales and 
marketing from headquarters, versus via company-owned subsidiaries versus using a 
distributor versus a multichannel strategy? What role do clusters or hotspots play in a de alio 
market entry? How can they help de alio commercialization processes? During the project, 
the team moved from parent company headquarters to a target industry cluster. How did this 
affect the commercialization project?  
Fourthly, it would also be interesting to conduct follow-up studies on the aspects of de alio 
partnering that were not part of the longitudinal scope of this case study. Potential themes 
would be: How does a de alio company create win-win propositions with potential partners, 
align business models with partners and maintain partnerships successfully (requires full 
confidentiality, may not be possible for researcher outside the company)? How does the 
situation of the de alio company evolve as the target market matures more? Are the 
developments supported by the theories of supposed rise of the dominant design, 
consolidation, shakeout of firms and the following growth phase? 
Furthermore, the following questions on which contribution is explicitly solicited in the 
academic community at present (Journal of Management Studies, 2016), are congruent with 
this study and would make interesting further research: 
What are the most useful conceptual models and empirical analyses of the 
antecedents, consequences, and contingencies associated with the processes of entry? 
How do the cognitive biases and decision heuristics of entrepreneurs and executives 
influence which opportunities related to market entry are discovered and how are 
they evaluated and exploited? 
What role do stakeholders, ecosystems, and networks play in entry processes? 
How do innovations, including business model and disruptive innovations, influence 
entry? 
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What roles do human resource practices play in the development and implementation 
of entry? 
Does de novo entry require different resource configurations than de alio entry? How 
and why do these differences matter? Does this change depend upon entry context? 
How do the interactions between a firm’s governance and its entry strategies affect 
performance and other outcomes? (Journal of Management Studies, 2016)  
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